References

evrazkar

Евразийский Кардиологический Журнал

Eurasian heart journal

2225-16852305-0748

Евразийская ассоциация кардиологов

10.38109/2225-1685-2022-3-6-56

evrazkar-6338

Research Article

КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ

CLINICAL GUIDELINES

Евразийские клинические рекомендации по профилактике и лечению сердечно-сосудистых заболеваний у больных с ожирением (2022)

Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022)

https://orcid.org/0000-0002-9822-4357

Чазова

И. Е.

Chazova

I. E.

Чазова Ирина Евгеньевна, д.м.н., профессор, академик РАН, заместитель генерального директора по научно-экспертной работе, руководитель отдела гипертонии, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Irina E. Chazova, Dr. of Sci. (Med.), Academician of RAS, Deputy General Director for Scientific and Expert Work, Head of Hypertension Department, A.L. Myasnikov Research Institute of Cardiology

Moscow

https://orcid.org/0000-0001-7895-9068

Жернакова

Ю. В.

Zhernakova

Yu. V.

Жернакова Юлия Валерьевна, профессор, д.м.н., ученый секретарь, НИИ клинической кардиологии им. А.Л. Мясникова

121552, Москва, ул. 3-я Черепковская, д. 15ателефон: +7-495-414-63-00

Yuliya V. Zhernakova, Prof., Dr. of Sci. (Med.), Scientific Secretary, A.L. Myasnikov Institute of Clinical Cardiology

3rd Cherepkovskaya street, 15a, Moscow, 121552Phone +7-495-414-63-00

juli001@mail.ru

https://orcid.org/0000-0001-5215-4894

Блинова

Н. В.

Blinova

N. V.

Блинова Наталия Владимировна, к.м.н., старший научный сотрудник отдела гипертонии, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Nataliya V. Blinova, Cand. of Sci. (Med.), Senior Researcher, Department of Hypertension, A.L. Myasnikov Institute of Clinical Cardiology

Moscow

https://orcid.org/0000-0002-8798-887X

Маркова

Т. Н.

Markova

T. N.

Маркова Татьяна Николаевна, д.м.н., зав. эндокринологическим отделением, врач-эндокринолог

Москва

Tat’yana N. Markova, Dr. of Sci. (Med.), head endocrinology department, endocrinologist

Moscow

https://orcid.org/0000-0001-8077-9381

Мазурина

Н. В.

Mazurina

N. V.

Мазурина Наталия Валентиновна, к.м.н., врач высшей квалификационной категории, ведущий научный сотрудник

Москва

Nataliya V. Mazurina, Cand. of Sci. (Med.), Leading Researcher

Moscow

https://orcid.org/0000-0002-4066-2661

Жиров

И. В.

Zhirov

I. V.

Жиров Игорь Витальевич, д.м.н., ведущий научный сотрудник, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Igor’ V. Zhirov, Dr. of Sci. (Med.), Leading Researcher, A.L. Myasnikov Institute of Clinical Cardiology

Moscow

https://orcid.org/0000-0003-4318-0315

Ускач

Т. М.

Uskach

T. M.

Ускач Татьяна Марковна, д.м.н., ведущий научный сотрудник, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Tat’yana M. Uskach, Dr. of Sci. (Med.), Leading Researcher, A.L. Myasnikov Institute of Clinical Cardiology

Moscow

https://orcid.org/0000-0003-3483-4698

Сафиуллина

А. А.

Safiullina

A. A.

Сафиуллина Альфия Ахатовна, к.м.н., младший научный сотрудник, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Al’fiya A. Safiullina, Cand. of Sci. (Med.), junior researcher, A.L. Myasnikov Institute of Clinical Cardiology

Moscow

https://orcid.org/0000-0002-5820-1759

Миронова

О. Ю.

Mironova

O. Iu.

Миронова Ольга Юрьевна, к.м.н., доцент

Москва

Olga Iu. Mironova, Dr. of Sci. (Med.), Prof.

Moscow

https://orcid.org/0000-0002-3140-5030

Елфимова

Е. М.

Elfimova

E. M.

Елфимова Евгения Михайловна, к.м.н., старший научный сотрудник лаборатории апноэ сна, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Evgeniya M. Elfimova, Cand. of Sci. (Med.), Senior Researcher, Sleep Apnea Laboratory, A.L. Myasnikov Institute of Clinical Cardiology

Moscow

https://orcid.org/0000-0001-5918-9969

Литвин

А. Ю.

Litvin

A. Yu.

Литвин Александр Юрьевич, д.м.н., профессор, главный научный сотрудник, руководитель лаборатории апноэ сна, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Alexander Yu. Litvin, Dr. of Sci. (Med.), Chief Researcher, Head of the Sleep Apnea Laboratory, A.L. Myasnikov Institute of Clinical Cardiology

Moscow

https://orcid.org/0000-0001-9163-0582

Железнова

Е. А.

Zheleznova

E. A.

Железнова Екатерина Александровна, к.м.н., лаборант- исследователь, врач-кардиолог, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Ekaterina A. Zheleznova, Cand. of Sci. (Med.), research laboratory assistant, cardiologist, A.L. Myasnikov Institute of Clinical Cardiology

Moscow

https://orcid.org/0000-0002-5532-6345

Юричева

Ю. А.

Yuricheva

Yu. A.

Юричева Юлия Александровна, к.м.н., научный сотрудник отдела клинической электрофизиологии и рентгенохирургических методов лечения нарушений ритма сердца, НИИ клинической кардиологии им. А.Л. Мясникова

Москва

Yuliya A. Yuricheva, Cand. of Sci. (Med.), Researcher, A.L. Myasnikov Institute of Clinical Cardiology

Moscow

https://orcid.org/0000-0001-5655-3913

Азизов

В. А.

Azizov

V. A.

Азизов Васадат Алиевич, д.м.н., профессор, заведующий кафедрой внутренних болезней

Баку

Vasadat A. Azizov, Dr. of Sci. (Med.), Professor, Head of the Department of Internal Diseases

Baku

https://orcid.org/0000-0002-8120-6267

Григоренко

Е. А.

Grigorenko

E. A.

Григоренко Елена Александровна, к.м.н., доцент, профессор кафедры кардиологии и внутренних болезней

Минск

Elena A. Grigorenko, Prof., Dr. of Sci. (Med.), Associate Professor, Professor of the Department of Cardiology and Internal Medicine

Minsk

Рахимов

З. Я.

Rahimov

Z. Ya.

Рахимов Закрия Яхьяевич, профессор, д.м.н., почётный профессор кафедры кардиологии с курсом клинической фармакологии ИПОСЗ РТ; председатель Ассоциации кардиологов РТ

Душанбе

Zakriya Ya. Rahimov, Prof., Dr. of Sci. (Med.), Honorary Professor of the Department of Cardiology with a course of clinical pharmacology; Chairman of the Association of Cardiologists of the Republic of Tajikistan

Dushanbe

Касымова

С. Д.

Kasymova

S. D.

Касымова Саломат Джамоловна, к.м.н., заведующая кафедрой эндокринологии

Душанбе

Salomat D. Kasymova, Cand. of Sci. (Med.), Head of the Department of Endocrinology

Dushanbe

Мустафаев

И. И.

Mustafaev

I. I.

Мустафаев Исах Исмаилович, д.м.н., профессор кафедры терапии

Баку

Isakh I. Mustafaev, Dr. of Sci. (Med.), Prof.

Baku

https://orcid.org/0000-0001-5728-3804

Нарзуллаева

А. Р.

Narzullaeva

A. R.

Нарзуллаева Адолат Рахматуллаевна, к.м.н., заведующая кафедрой кардиологии с курсом клинической фармакологии

Душанбе

Adolat R. Narzullaeva, Cand. of Sci. (Med.), Head of the Department of Cardiology with the Course of Clinical Pharmacology

Dushanbe

Полупанов

А. Г.

Polupanov

A. G.

Полупанов Андрей Геннадьевич, д.м.н., профессор, старший научный сотрудник

Бишкек

Andrey G. Polupanov, Dr. of Sci. (Med.), Prof., Senior Researcher

Bishkek

https://orcid.org/0000-0003-2172-9776

Сарыбаев

А. Ш.

Sarybaev

A. Sh.

Сарыбаев Акпай Шогаибович, д.м.н., профессор, директор

Бишкек

Akpaj Sh. Sarybaev, Dr. of Sci. (Med.), Prof., Director

Bishkek

Срожидинова

Н. З.

Srozhidinova

N. Z.

Срожидинова Нигора Зайнидиновна, д.м.н., ученый секретарь

Ташкент

Nigora Z. Srozhidinova, Dr. of Sci. (Med.), Scientific Secretary

Tashkent

Российская академия наук; ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова» Минздрава РоссииРоссияRussian Academy of Sciences; E.I. Chazov National Medical Research Center of CardiologyRussian Federation

ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова» Минздрава РоссииРоссияE.I. Chazov National Medical Research Center of CardiologyRussian Federation

ГБУЗ «Городская клиническая больница № 52 Департамента здравоохранения города Москвы»РоссияCity Clinical Hospital No. 52Russian Federation

ФГБУ «НМИЦ эндокринологии» Минздрава РоссииРоссияNational Research Center for EndocrinologyRussian Federation

ФГАОУ ВО Первый МГМУ им. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation

1-ый Азербайджанский Медицинский УниверситетАзербайджан1st Azerbaijan Medical UniversityAzerbaijan

Учреждение образования «Белорусский государственный медицинский университет»БеларусьBelarusian State Medical UniversityBelarus

Институт последипломного образования в сфере здравоохранения; Ассоциации кардиологов РТТаджикистанInstitute of Postgraduate Education in Healthcare; Association of Cardiologists of the Republic of TajikistanTajikistan

Институт последипломного образования в сфере здравоохраненияТаджикистанInstitute of Postgraduate Education in HealthcareTajikistan

Азербайджанский институт усовершенствования врачей им. А. АлиеваАзербайджанAzerbaijan State Advanced Training Institute for Doctors named by A.AliyevAzerbaijan

Национальный центр кардиологии и терапии им. академика М.М. Миррахимова при Минздраве Киргизской РеспубликиКыргызстанMM. Mirrakhimov National Center for Cardiology and TherapyKyrgyzstan

Республиканский специализированный научно-практический медицинский центр кардиологииУзбекистанRepublican Specialized Scientific and Practical Medical Center for CardiologyUzbekistan

2022

10012022

03656

Copyright © Чазова И.Е., Жернакова Ю.В., Блинова Н.В., Маркова Т.Н., Мазурина Н.В., Жиров И.В., Ускач Т.М., Сафиуллина А.А., Миронова О.Ю., Елфимова Е.М., Литвин А.Ю., Железнова Е.А., Юричева Ю.А., Азизов В.А., Григоренко Е.А., Рахимов З.Я., Касымова С.Д., Мустафаев И.И., Нарзуллаева А.Р., Полупанов А.Г., Сарыбаев А.Ш., Срожидинова Н.З., 2022

2022

Чазова И.Е., Жернакова Ю.В., Блинова Н.В., Маркова Т.Н., Мазурина Н.В., Жиров И.В., Ускач Т.М., Сафиуллина А.А., Миронова О.Ю., Елфимова Е.М., Литвин А.Ю., Железнова Е.А., Юричева Ю.А., Азизов В.А., Григоренко Е.А., Рахимов З.Я., Касымова С.Д., Мустафаев И.И., Нарзуллаева А.Р., Полупанов А.Г., Сарыбаев А.Ш., Срожидинова Н.З.

Chazova I.E., Zhernakova Y.V., Blinova N.V., Markova T.N., Mazurina N.V., Zhirov I.V., Uskach T.M., Safiullina A.A., Mironova O.I., Elfimova E.M., Litvin A.Y., Zheleznova E.A., Yuricheva Y.A., Azizov V.A., Grigorenko E.A., Rahimov Z.Y., Kasymova S.D., Mustafaev I.I., Narzullaeva A.R., Polupanov A.G., Sarybaev A.S., Srozhidinova N.Z.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.heartj.asia/jour/article/view/6338

Отказ от ответственности. Рекомендации ЕАК отражают точку зрения ЕАК и были подготовлены после тщательного изучения научных и медицинских данных, имеющихся на момент их публикации. ЕАК не несут ответственности в случае какого-либо противоречия, несоответствия и / или неоднозначности между Рекомендациями ЕАК и любыми другими официальными рекомендациями или руководствами, выпущенными соответствующими органами общественного здравоохранения, в частности, в отношении правильного использования медицинских или терапевтических стратегий. Медицинским работникам рекомендуется в полной мере учитывать Рекомендации ЕАК при оценке своего клинического суждения, а также при определении и реализации профилактических, диагностических или терапевтических медицинских стратегий. Тем не менее, Рекомендации ЕАК никоим образом не отменяют индивидуальную ответственность медицинских работников за принятие надлежащих и точных решений с учетом состояния здоровья каждого пациента и в консультации с этим пациентом и, при необходимости и / или необходимости, опекуна пациента. Рекомендации ЕАК не освобождают медицинских работников от полного и тщательного рассмотрения соответствующих официальных обновленных рекомендаций или руководств, выпущенных компетентными органами общественного здравоохранения, для рассмотрения каждого медицинского случая в свете современных научно обоснованных рекомендаций в соответствии с их этическими и профессиональными обязательствами. Кроме того, медицинский работник обязан проверять действующие правила и положения, касающиеся лекарств и медицинских изделий, на момент назначения по рецепту.

Disclaimer. The EAC Guidelines represent the views of the EAC, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The EAC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the EAC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the EAC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the EAC Guide-lines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the EAC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

ожирениеартериальная гипертониясердечно-сосудистые заболеванияИБСнарушения ритмаХСН

obesityarterial hypertensioncardiovascular diseasesischemic heart diseasearrhythmiasCHF

Члены Рабочей группы подтвердили отсутствие финансовой поддержки / конфликта интересов

Members of the Working Group confirmed the lack of financial support / conflict of interest

References1

Глобальный план действий по профилактике неинфекционных заболеваний и борьбе с ними на 2013-2020 гг. ВОЗ, Женева, Швейцария; 2013:107с. WHO.URL: http://www.who.int/nmh/events/ncd_action_plan/en/#.

Global action plan for the prevention and control of noncommunicable diseases 2013-2020. WHO. URL: http://www.who.int/nmh/events/ncd_action_plan/en/# (In Russ.)

Шальнова С.А., Деев А.Д. Масса тела у мужчин и женщин (результаты обследования российской, национальной, представительной выборки населения) Кардиоваскулярная терапия и профилактика. 2008;7(6):60-3.

Shalnova SA, Deev AD. Body mass in men and women: the Russian national representative sample data. Cardiovascular Therapy and Prevention. 2008;7(6):60-3. (In Russ.)

Шальнова С.А., ДеевА.Д., Баланова Ю.А., и др. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика, 2017;16(4):4-10. https://doi.org/10.15829/1728-8800-2017-4-4-10

Shalnova SA, Deev AD, Balanova YuA, et al. Twenty years trends of obesity and arterial hypertension and their association In Russia. Cardiovascular Therapy and Prevention 2017;16(4):4-10, (In Russ.). https://doi.org/10.15829/1728-8800-2017-4-4-10

Баланова Ю.А., Шальнова С.А., Деев А.Д., Имаева А.Э., Концевая А.В., Муромцева Г.А., Капустина А.В., Евстифеева С.Е., Драпкина О.В. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-130. https://doi.org/10.15829/1560-4071-2018-6-123-130

Misra A, Jayawardena R, Anoop S. Obesity in South Asia: Phenotype, Morbidities, and Mitigation. Curr Obes Rep. 2019;8(1):43-52. https://doi.org/10.1007/s13679-019-0328-0

Cheng L, Yan W, Zhu L, et al. Comparative analysis of IDF, ATPIII and CDS in the diagnosis of metabolic syndrome among adult inhabitants in Jiangxi Province, China. PLoS One. 2017;12(12):e0189046. https://doi.org/10.1371/journal.pone.0189046

Nishida C, Barba C, Cavalli-Sforza T, et al. Appropriate bodymass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163. https://doi.org/10.1016/S0140-6736(03)15268-3

Pan W-H, Yeh W-T. How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations. Asia Pac J Clin Nutr. 2008. https://doi.org/10.6133/apjcn.2008.17.3.02

Nam GE, Park HS. Perspective on Diagnostic Criteria for Obesity and Abdominal Obesity in Korean Adults. J Obes Metab Syndr. 2018;27(3):134-142. https://doi.org/10.7570/jomes.2018.27.3.134

Zeng Q, He Y, Dong S, et al. Optimal cut-off values of BMI, waist circumference and waist:height ratio for defining obesity in Chinese adults. Br J Nutr. 2014;112(10):1735-1744. https://doi.org/10.1017/S0007114514002657

Jih J, Mukherjea A, Vittinghoff E, et al. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. Prev Med (Baltim). 2014;65:1-6. https://doi.org/10.1016/j.ypmed.2014.04.010

Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring). 2020 Jul; 28(7):1195-1199. https://doi.org/10.1002/oby.22831

Ekelund, U et al. Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC) American Journal of Clinical Nutrition. Am J Clin Nutr. 2015 Mar; 101(3):613-621. https://doi.org/10.3945/ajcn.114.100065

Blüher M. O. Metabolically Healthy Obesity. Endocrine Reviews, June 2020; 41(3):1-16. https://doi.org/10.1210/endrev/bnaa004

Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol. 2017;70(12):1429-1437. https://doi.org/10.1016/j.jacc.2017.07.763

Fan J, Song Y, Chen Y, Hui R, Zhang W. Combined effect of obesity and cardio-metabolic abnormality on the risk of cardiovascular disease: a metaanalysis of prospective cohort studies. Int J Cardiol. 2013;168(5):4761-4768. https://doi.org/10.1016/j.ijcard.2013.07.230

Zheng R, Zhou D, Zhu Y. The long-term prognosis of cardiovascular disease and all-cause mortality for metabolically healthy obesity: a systematic review and meta-analysis. J Epidemiol Community Health. 2016;70(10):1024-1031. https://doi.org/10.1136/jech-2015-206948

Moussa O, Arhi C, Ziprin P, Darzi A, Khan O, Purkayastha S. Fate of the metabolically healthy obese-is this term a misnomer? A study from the Clinical Practice Research Datalink. Int J Obes (Lond). 2019;43(5):1093-1101. https://doi.org/10.1038/s41366-018-0096-z

Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758-769. https://doi.org/10.7326/0003-4819-159-11-201312030-00008

Frank L.J. Visseren, Francois Mach, Yvo M. Smulders, David Carballo, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42:3227-3337. https://doi.org/10.1093/eurheartj/ehab484

Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 1991;266:231-236. PMID: 1829117

Lambert E, Sari CI, Dawood T, Nguyen J, McGrane M, Eikelis N, Chopra R, Wong C, Chatzivlastou K, Head G, Straznicky N, Esler M, Schlaich M, Lambert G. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults.Hypertension. 2010;56:351-358. https://doi.org/10.1161/hypertensionaha.110.155663

Железнова Е.А., Жернакова Ю.В., Погорелова О.А. и др. Состояние сосудистой стенки и его связь с периваскулярной жировой тканью и другими жировыми депо у пациентов молодого возраста с абдоминальным ожирением. Системные гипертензии. 2019;16(4):80-86https://syst-hypertension.ru/2075-082X/article/view/33559

Zheleznova E.A., Zhernakova J.V., Pogorelova O.A., Tripoten M.I., Blinova N.V., Shariya M.A., Azimova M.O., Gorieva S.B., Maslov A.V., Balakhonova T.V., Chazova I.E. Vascular wall status and its link with perivascular adipose tissue and other fat depots in young patients with abdominal obesity. Systemic Hypertension. –2019;16(4):80-86 (In Russ.). https://syst-hypertension.ru/2075-082X/article/view/33559

Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. The natural course of healthy obesity over 20 years. J Am Coll Cardiol 2015;65:101-102. https://doi.org/10.1016/j.jacc.2014.09.077

Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16(1):6-31. https://doi.org/10.26442/2075082X.2019.1.190179

Chazova I.E., Zhernakova Y.V. Diagnosis and treatment of arterial hypertension [Guidelines]. Systemic Hypertension. 2019;16(1):6-31. https://doi.org/10.26442/2075082X.2019.1.190179

SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439-2454. https://doi.org/10.1093/eurheartj/ehab309

SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455-2467. https://doi.org/10.1093/eurheartj/ehab312

Ожирение у взрослых. Клинические рекомендации Минздрава России, 2020.

World Health Organization. Obesity: preventing and managing the global epidemic. 1997, Geneva: WHO.

Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009 Mar 28;373(9669):1083-96. https://doi.org/10.1016/S0140-6736(09)60318-4. Epub 2009 Mar 18. PMID: 19299006; PMCID: PMC2662372.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res. 1998 Sep;6 Suppl 2:51S-209S. Erratum in: Obes Res 1998 Nov;6(6):464. PMID: 9813653.

Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:I-XII, 1-253. PMID: 11234459.

Garvey WT, Garber AJ, Mechanick JI, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977-989. https://doi.org/10.4158/ep14280.ps

Tsai AG, Wadden TA. In the clinic: obesity. Ann Intern Med. 2013 Sep 3;159(5):ITC3-1-ITC3-15; quiz ITC3-16. https://doi.org/10.7326/0003-4819-159-5-201309030-01003. PMID: 24026335.

Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427. https://doi.org/10.1056/nejm199908053410607

Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014. JAMA 2016; 315:2292. https://doi.org/10.1001/jama.2016.6361

Van Pelt RE, Gavin KM, Kohrt WM. Regulation of Body Composition and Bioenergetics by Estrogens. Endocrinol Metab Clin North Am 2015;44:663. https://doi.org/10.1016/j.ecl.2015.05.011

Kohrt WM, Wierman ME. Preventing Fat Gain by Blocking Follicle-Stimulating Hormone. N Engl J Med 2017;377:293. https://doi.org/10.1056/nejmcibr1704542

Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of WHO/IDF Consultation. 2006

Pearce E. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes. 2012;19:408-13. https://doi.org/10.1097/med.0b013e328355cd6c

Daniel E, Newell-Price J. Cushing’s syndrome. Medicine. 2017;45(8):475-9.

Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrin Metab. 2010;95:3614-7. https://doi.org/10.1210/jc.2010-1245

Rotondi M, Magri F, Chiovato L. Thyroid and obesity: not a one-way interaction. J Clin Endocrin Metab. 2011;96:344-6. https://doi.org/10.1210/jc.2010-2515

Laurberg P, Knudsen N, Andersen S, et al. Thyroid function and obesity. Eur Thyroid J. 2012;1:159-67. https://doi.org/10.1159/000342994

Duntas L, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013;23:646-53. https://doi.org/10.1089/thy.2011.0499

Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3121-31. https://doi.org/10.1210/jc.2009-0612

Auriemma R. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018;13(2):99-106. https://doi.org/10.1080/17446651.2018.1434412

Dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity. 2011;19:800-5. https://doi.org/10.1038/oby.2010.150

Lohman, T.G., Roche, A.F. and Martorell, R. (1988) Anthropometric standardization reference manual. Human Kinetics Books, Chicago.

Ford ES, Mokdad AH, Giles WH. Trends in waist circumference among U.S. adults. Obes Res. 2003 Oct;11(10):1223-31. https://doi.org/10.1038/oby.2003.168. PMID: 14569048.

Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J, Allison TG, Batsis JA, Sert-Kuniyoshi FH, Lopez-Jimenez F. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond). 2008;32:959-966. https://doi.org/10.1038/ijo.2008.11

Pack QR, Rodriguez-Escudero JP, Thomas RJ, Squires RW, Johnson L, Somers VK, Lopez-Jimenez F. Diagnostic performance of weight loss to predict body fatness improvement in cardiac rehabilitation patients. J Cardiopulm Rehabil Prev. 2013;33:68-76. https://doi.org/10.1097/HCR.0b013e31827fe7e3

Okorodudu DO, Jumean MF, Montori VM, Romero-Corral A, Somers VK, Erwin PJ, Lopez-Jimenez F. Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis. Int J Obes (Lond). 2010;34:791-799. https://doi.org/10.1038/ijo.2010.5

Heymsfield SB, Peterson CM, Thomas DM, Heo M, Schuna JM Why are there race/ethnic differences in adult body mass index-adiposity relationships? A quantitative critical review. Obes Rev. 2016;17:262-275. https://doi.org/10.1111/obr.12358

Rao G, Powell-Wiley TM, Ancheta I, Hairston K, Kirley K, Lear SA, North KE, Palaniappan L, Rosal MC; on behalf of the American Heart Association Obesity Committee of the Council on Lifestyle and Cardiometabolic Health. Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association [published correction appears in Circulation. 2015;132:e130]. Circulation. 2015;132:457-472. https://doi.org/10.1161/CIR.0000000000000223

Чазова И.Е. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями / И.Е. Чазова, Недогода С.В., Жернакова Ю.В. и др. Кардиологический вестник. 2014;1:3-57.

Дедов И.И., Шестакова М.В., Мельниченко Г.А., Мазурина Н.В., Андреева Е.Н. и соавт. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний» Ожирение и метаболизм. 2021;18(1):5-99. https://doi.org/10.14341/omet12714

Kim H, Caulfield LE, Rebholz CM. Healthy Plant-Based Diets Are Associated with Lower Risk of All-Cause Mortality in US Adults. J Nutr. 2018;148(4):624-631. https://doi.org/10.1093/jn/nxy019

Satija A, Bhupathiraju SN, Spiegelman D, et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary Heart Disease in U.S. Adults. J Am Coll Cardiol. 2017;70(4):411-422. https://doi.org/10.1016/j.jacc.2017.05.047

Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Association of Changes in Diet Quality with Total and Cause Specific Mortality. N Engl J Med. 2017;377(2):143-153. https://doi.org/10.1056/NEJMoa1613502

Alberti K.G. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation / K.G. Alberti, P.Z. Zimmet // Diabet Med. 1998;15:539.

Silver HJ, Welch EB, Avison MJ, Niswender KD: Imaging body composition in obesity and weight loss: challenges and opportunities. Diabetes Metab Syndr Obes 2010;3:337-347. https://doi.org/10.2147/dmsott.s9454

Bolanowski M, Nilsson BE: Assessment of human body composition using dual-energy x-ray absorptiometry and bioelectrical impedance analysis. Med Sci Monit 2001;7:1029-1033. PMID: 11535954

Cornier M-A, Després J-P, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge M-P,Towfighi A, Poirier P; on behalf of the American Heart Association Obesity Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Radiology and Intervention,Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Stroke Council: Assessing adiposity: a scientific statement from the American Heart Association. Circulation 2011;124:1996-2019. https://doi.org/10.1161/CIR.0b013e318233bc6a

Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H; Obesity Management Task Force of the European Association for the Study of Obesity. European Guidelines for Obesity Management in Adults. Obes Facts. 2015;8(6):402-24. doi: 10.1159/000442721. Epub 2015 Dec 5. Erratum in: Obes Facts. 2016;9(1):64. PMID: 26641646; PMCID: PMC5644856.

LaForgia, J., Dollman, J., Dale, M.J., Withers, R.T. and Hill, A.M. (2009), Validation of DXA Body Composition Estimates in Obese Men and Women. Obesity, 17: 821-826. https://doi.org/10.1038/oby.2008.595

Adult Obesity Algorithm eBook: Detailed overview of Obesity Medicine Bays HE, McCarthy W, Burridge K, Tondt J, Karjoo S, Christensen S, Ng J, Golden A, Davisson L, Richardson L. Obesity Algorithm eBook, presented by the Obesity Medicine Association. 2021; https://obesitymedicine.org/obesity-algorithm/ (Accessed = Insert date)

Aragon, A.A., Schoenfeld, B.J., Wildman, R. et al. International society of sports nutrition position stand: diets and body composition. J Int Soc Sports Nutr. 14,16(2017). https://doi.org/10.1186/s12970-017-0174-y

Völgyi E, Tylavsky FA, Lyytikäinen A, Suominen H, Alén M, Cheng S. Assessing body composition with DXA and bioimpedance: effects of obesity, physical activity, and age. Obesity (Silver Spring). 2008 Mar;16(3):700-5. https://doi.org/10.1038/oby.2007.94. Epub 2008 Jan 17. PMID: 18239555.

Fakhrawi DH, Beeson L, Libanati C, Feleke D, Kim H, Quansah A, Darnell A, Lammi-Keefe CJ, Cordero-MacIntyre Z. Comparison of body composition by bioelectrical impedance and dual-energy x-ray absorptiometry in overweight/obese postmenopausal women. J Clin Density. 2009 Apr-Jun; 12(2):238-44. https://doi.org/10.1016/j.jocd.2009.01.004. Epub 2009 Mar 13. PMID: 19285894.

Bray GA, DeLany JP, Volaufova J, Harsha DW, Champagne C. Prediction of body fat in 12-y-old African American and white children: evaluation of methods. Am J Clin Nutr. 2002 Nov;76(5):980-90. https://doi.org/10.1093/ajcn/76.5.980. PMID: 12399269.

Hankinson SJ, Williams CH, Ton VK, Gottlieb SS, Hong CC. Should we overcome the resistance to bioelectrical impedance in heart failure? Expert Rev Med Devices. 2020 Aug;17(8):785-794. https://doi.org/10.1080/17434440.2020.1791701. Epub 2020 Jul 13. PMID: 32658589; PMCID: PMC8356137.

Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010. https://doi.org/10.1161/CIR.0000000000000973. PMID: 33882682; PMCID: PMC8493650.

Neeland IJ, Poirier P, Després JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management.Circulation. 2018;137:1391-1406. https://doi.org/10.1161/CIRCULATIONAHA.117.029617

Sjöström L. A computer-tomography based multicompartment body composition technique and anthropometric predictions of lean body mass, total and subcutaneous adipose tissue. Int J Obes. 1991 Sep;15 Suppl 2:19-30. PMID: 1794934.

Shah RV, Anderson A, Ding JZ, Budoff M, Rider O, Petersen SE, Jensen MK, Koch M, Allison M, Kawel-Boehm N, et al.. Pericardial, but not hepatic, fat by CT Is Associated With cv outcomes and structure: the Multi-Ethnic Study of Atherosclerosis.JACC Cardiovasc Imag. 2017;10:1016-1027. https://doi.org/10.1016/j.jcmg.2016.10.024

Hruskova J, Maugeri A, Podrouzkova H, Stipalova T, Jakubik J, Barchitta M, Medina-Inojosa JR, Homolka M, Agodi A, Kunzova S, et al.. Association of cardiovascular health with epicardial adipose tissue and intima media thickness: the Kardiovize study.J Clin Med. 2018; 7:113. https://doi.org/10.3390/jcm7050113

Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, Di Mario U, Leonetti F. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk.J Clin Endocrinol Metab. 2003; 88:5163-5168. https://doi.org/10.1210/jc.2003-030698

Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O’Donnell CJ, Fox CS, Hoffmann U. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study.Eur Heart J. 2009; 30:850-856. https://doi.org/10.1093/eurheartj/ehn573

Ong KL, Ding J, McClelland RL, Cheung BM, Criqui MH, Barter PJ, Rye KA, Allison MA. Relationship of pericardial fat with lipoprotein distribution: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015;241:664-670. https://doi.org/10.1016/j.atherosclerosis.2015.06.027

Elming MB, Lønborg J, Rasmussen T, Kühl JT, Engstrøm T, Vejlstrup N, Køber L, Kofoed KF. Measurements of pericardial adipose tissue using contrast enhanced cardiac multidetector computed tomography-comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging. 2013 Aug;29(6):1401-7. https://doi.org/10.1007/s10554-013-0218-6. PMID: 23702948.

Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:1189-1196. https://doi.org/10.3945/ajcn.2010.29673

Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Fito M, Gea A, Hernan MA, Martinez-Gonzalez MA, PREDIMED Study Investigators. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med 2018;378:e34. https://doi.org/10.1056/nejmoa1800389

Brader L, Uusitupa M, Dragsted LO, Hermansen K. Effects of an isocaloric healthy Nordic diet on ambulatory blood pressure in metabolic syndrome: a randomized SYSDIET sub-study. Eur J Clin Nutr 2014;68(1):57-63. https://doi.org/10.1038/ejcn.2013.192

Mykkänen OT, Huotari A, Herzig KH et al. Wild blueberries (Vaccinium myrtillus) alleviate inflammation and hypertension associated with developing obesity in mice fed with a high-fat diet. PLoS One 2014;9(12):114790. https://doi.org/10.1371/journal.pone.0114790

Erlund I, Koli R, Alfthan G et al. Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. Am J Clin Nutr 2008; 87(2):323-31. https://doi.org/10.1093/ajcn/87.2.323

Yokoyama Y, Nishimura K, Barnard ND et al. Vegetarian diets and blood pressure: a meta-analysis. JAMA Intern Med 2014;174(4):577-87. https://doi.org/10.1001/jamainternmed.2013.14547

Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997; 336(16):1117-24. https://doi.org/10.1056/nejm199704173361601

Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54 (3): 475–81. DOI: 10.1161/HYPERTENSIONAHA.109.131235

Appel LJ, Espeland MA, Easter L et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001;161(5):685-93. https://doi.org/10.1001/archinte.161.5.685

Cook NR, Cutler JA, Obarzanek E et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007;334(7599):885-8. https://doi.org/10.1136/bmj.39147.604896.55

Chang HY, Hu YW, Yue CS et al. Effect of potassium-enriched salt on cardiovascular mortality and medical expenses of elderly men. Am J Clin Nutr 2006;83(6):1289-96. https://doi.org/10.1093/ajcn/83.6.1289

He FJ, MacGregor GA. Salt reduction lowers cardiovascular risk: meta-analysis of outcome trials. Lancet 2011;378(9789):380-2. https://doi.org/10.1016/S0140-6736(11)61174-4

Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: metaanalysis of prospective studies. BMJ 2009;339:b4567. https://doi.org/10.1136/bmj.b4567

Frohlich ED. The salt conundrum: a hypothesis. Hypertension. 2007;50(1):161-6. https://doi.org/10.1161/hypertensionaha.107.088328

Streppel MT, Arends LR, van't Veer P et al. Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med 2005;165(2):150-6. https://doi.org/10.1001/archinte.165.2.150

Whelton SP, Hyre AD, Pedersen B et al. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J Hypertens 2005;23(3):475-81. https://doi.org/10.1097/01.hjh.0000160199.51158.cf

Vernay M, Aïdara M, Salanave B et al. Diet and blood pressure in 18–74-year-old adults: the French Nutrition and Health Survey (ENNS, 2006-2007). J Hypertens 2012;30(10):1920-7. https://doi.org/10.1097/hjh.0b013e328356c59f

Gopinath B, Flood VM, Rochtchina E et al. Influence of high glycemic index and glycemic load diets on blood pressure during adolescence. Hypertension 2012;59(6):1272-7. https://doi.org/10.1161/HYPERTENSIONAHA.112.190991

100

Oude Griep LM, Stamler J, Chan Q, Van Horn L, Steffen LM, Miura K, Ueshima H, Okuda N, Zhao L, Daviglus ML, Elliott P; INTERMAP Research Group. Am J Clin Nutr. 2013 May;97(5):1083-91. https://doi.org/10.3945/ajcn.112.046300

101

Hartley L, May MD, Loveman E et al. Dietary fibre for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2016;1:CD011472. https://doi.org/10.1002/14651858.CD011472.pub

102

Bozzetto L, Costabile G, Della Pepa G et al. Dietary Fibre as a Unifying Remedy for the Whole Spectrum of Obesity-Associated Cardiovascular Risk. Nutrients 2018;10(7):pii:E943. https://doi.org/10.3390/nu10070943

103

Smith CF, Williamson DA, Bray GA, Ryan DH. Flexible vs. Rigid dieting strategies: relationship with adverse behavioral outcomes. Appetite 1999; 32(3):295-305. https://doi.org/10.1006/appe.1998.0204

104

Stewart TM, Williamson DA, White MA. Rigid vs. flexible dieting: association with eating disorder symptoms in nonobese women. Appetite 2002;38(1):39-44. https://doi.org/10.1006/appe.2001.0445

105

Timko CA, Perone J. Rigid and flexible control of eating behavior in a college population. Eating behaviors 2005;6(2):119–25. https://doi.org/10.1016/j.eatbeh.2004.09.002

106

Westenhoefer J, Stunkard AJ, Pudel V. Validation of the flexible and rigid control dimensions of dietary restraint. Int J Eat Disord 1999;26(1):53-64. https://doi.org/10.1002/(sici)1098-108x(199907)26:1%3C53::aid-eat7%3E3.0.co;2-n

107

Davoodi SH, Ajami M, Ayatollahi SA et al. Calorie Shifting Diet Versus Calorie Restriction Diet: A Comparative Clinical Trial Study. Int J Prev Med 2014;5(4):447-56. PMID: 24829732 PMCID: PMC4018593

108

Adamsson V, Reumark A, Fredriksson I-B et al. Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolemic subjects: a randomized controlled trial [NORDIET]. J Intern Med 2011; 269: 150–9.

109

Eilat-Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients 2013;5:36463683. https://doi.org/10.3390/nu5093646

110

European Heart Network. Transforming European food and drink policies for cardiovascular health. http://www.ehnheart.org/publications-and-papers/publications/1093:transforming-european-food-and-drinks-policies-for-cardiovascular-health.html (21 July 2020).

111

Mensink RP. Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis https://apps.who.int/iris/bitstream/handle/10665/246104/9789241565349-eng.pdf?sequence=1 (21 July 2020).

112

Guasch-Ferre M, Satija A, Blondin SA, Janiszewski M, Emlen E, O’Connor LE, Campbell WW, Hu FB, Willett WC, Stampfer MJ. Meta-Analysis of Randomized Controlled Trials of Red Meat Consumption in Comparison With Various Comparison Diets on Cardiovascular Risk Factors. Circulation 2019;139:1828-1845. https://doi.org/10.1161/circulationaha.118.035225

113

He FJ, Tan M, Ma Y, MacGregor GA. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:632-647. https://doi.org/10.1016/j.jacc.2019.11.055

114

Willett W, Rockstrom J, Loken B, Springmann M, Lang T, Vermeulen S, Garnett T, Tilman D, et al. Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems. Lancet 2019;393:447-492. https://doi.org/10.1016/s0140-6736(18)31788-4

115

116

Zeraatkar D, Johnston BC, Bartoszko J, Cheung K, Bala MM, Valli C, Rabassa M, Sit D, Milio K, Sadeghirad B, Agarwal A, Zea AM, Lee Y, Han MA, Vernooij RWM, Alonso-Coello P, Guyatt GH, El Dib R. Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic Review of Randomized Trials. Ann Intern Med 2019;171:721-731. https://doi.org/10.7326/m19-0622

117

Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012;15:725-737. https://doi.org/10.1017/s1368980011002254

118

Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H, et al. Association Between Soft Drink Consumption and Mortality in 10 European Countries. JAMA Intern Med 2019;179:1479-1490. https://doi.org/10.1001/jamainternmed.2019.2478

119

World Health Organization. Guideline: sugars intake for adults and children. https://www.who.int/publications/i/item/9789241549028 (21 July 2020)

120

Howell S, Kones R. "Calories in, calories out" and macronutrient intake: the hope, hype, and science of calories. Am J Physiol Endocrinol Metab 2017;313:E608-E612. https://doi.org/10.1152/ajpendo.00156.2017

121

Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2015;3:968-979. https://doi.org/10.1016/S2213-8587(15)00367-8

122

Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev 2016;17:1001-1011. https://doi.org/10.1111/obr.12433

123

Wing RR, Espeland MA, Clark JM, Hazuda HP, Knowler WC, Pownall HJ, Unick J, Wadden T, Wagenknecht L, Action for Health in Diabetes (Look AHEAD) Study Group. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial. Diabetes Care 2016;39:1345-1355. https://doi.org/10.2337/dc16-0509

124

Doukky R, Mangla A, Ibrahim Z, et al. Impact of Physical Inactivity on Mortality in Patients With Heart Failure. Am J Cardiol. 2016;117(7):1135-1143. https://doi.org/10.1016/j.amjcard.2015.12.060

125

Liu Y, Lee DC, Li Y, Zhu W, Zhang R, Sui X, Lavie CJ, Blair SN. Associations of Resistance Exercise with Cardiovascular Disease Morbidity and Mortality. Med Sci Sports Exerc 2019;51:499-508. https://doi.org/10.1249/mss.0000000000001822

126

Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske AR, Prokop LJ, Vinciguerra M, Lopez-Jimenez F. The association of resistance training with mortality: A systematic review and meta-analysis. Eur J Prev Cardiol 2019;26:1647-1665. https://doi.org/10.1177/2047487319850718

127

Ortega FB, Silventoinen K, Tynelius P, Rasmussen F. Muscular strength in male adolescents and premature death: cohort study of one million participants. BMJ 2012;345:e7279. https://doi.org/10.1136/bmj.e7279

128

Volaklis KA, Halle M, Meisinger C. Muscular strength as a strong predictor of mortality: A narrative review. Eur J Intern Med 2015;26:303-310. https://doi.org/10.1016/j.ejim.2015.04.013

129

Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J 2021;42:1796. https://doi.org/10.1093/eurheartj/ehaa605

130

Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP, American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011;43:1334-1359. https://doi.org/10.1249/mss.0b013e318213fefb

131

Kraus WE, Powell KE, Haskell WL, Janz KF, Campbell WW, Jakicic JM, Troiano RP, Sprow K, Torres A, Piercy KL, 2018 Physical Activity Guidelines Advisory Committee. Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease. Med Sci Sports Exerc 2019;51:1270-1281. https://doi.org/10.1249/mss.0000000000001939

132

Powell KE, King AC, Buchner DM, Campbell WW, DiPietro L, Erickson KI, Hillman CH, Jakicic JM, Janz KF, Katzmarzyk PT, Kraus WE, Macko RF, Marquez DX, McTiernan A, Pate RR, Pescatello LS, Whitt-Glover MC. The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition. J Phys Act Health 2018:111. https://doi.org/10.1123/jpah.2018-0618

133

Sattelmair J, Pertman J, Ding EL, Kohl HW, 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 2011;124:789-795. https://doi.org/10.1161/circulationaha.110.010710

134

Hupin D, Roche F, Gremeaux V, Chatard JC, Oriol M, Gaspoz JM, Barthelemy JC, Edouard P. Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged >/=60 years: a systematic review and meta-analysis. Br J Sports Med 2015;49:1262-1267. http://dx.doi.org/10.1136/bjsports-2014-094306

135

Cradock KA, OL G, Finucane FM, Gainforth HL, Quinlan LR, Ginis KA. Behaviour change techniques targeting both diet and physical activity in type 2 diabetes: A systematic review and meta-analysis. Int J Behav Nutr Phys Act 2017;14:18. https://doi.org/10.1186/s12966-016-0436-0

136

Brickwood KJ, Watson G, O’Brien J, Williams AD. Consumer-Based Wearable Activity Trackers Increase Physical Activity Participation: Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth 2019;7:e11819. https://doi.org/10.2196/11819

137

Torgeson J.S., Hauptman J. XENical in the prevention of diabetes in obese subjects subjects (XENDOS) study. Diabetes Care. 2004;27:155-161. https://doi.org/10.2337/diacare.27.1.155

138

Rossner S., Sjostrom L., Noack R. et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.Obes. Res. 2000;8(1): 49-61. https://doi.org/10.1038/oby.2000.8

139

Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med.2015;373(1):11-22. https://doi.org/10.1056/NEJMoa1411892

140

le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet. 2017;389(10077):1399-1409. https://doi.org/10.1016/s0140-6736(17)30069-7

141

Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. https://doi.org/10.1038/ij o.2016.52

142

Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity. 2013;37:1443-1451; https://doi.org/10.1038/ijo.2013.120

143

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. https://doi.org/10.1056/NEJMoa1603827

144

TA Wadden, P Hollander, S Klein et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. International Journal of Obesity. 2013;37:1443-1451; https://doi.org/10.1038/ijo.2013.120

145

legal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a sys- tematic review and meta-analysis. JAMA 2013;309:71-82. https://doi.org/10.1001/jama.2012.113905

146

Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N, Wormser D, Gao P, et al. Body-mass index and all-cause mortality: individual- participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016;388:776-786. https://doi.org/10.1016/s0140-6736(16)30175-1

147

Rucker D., Padwal R., Li S. et al. Long term pharmacotherapy for obesity and overweight updated meta-analysis. British Medical Journal 2007; 335: 1194-1199.

148

Avenell A., Broom J., Brown T. et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004, May;8(21):iii-iv,1-182. https://doi.org/10.3310/hta8210

149

Biddle SJH, Bengoechea García E, Pedisic Z, et al. Screen Time, Other Sedentary Behaviours, and Obesity Risk in Adults: A Review of Reviews. Curr Obes Rep. 2017;6(2):134-147. https://doi.org/10.1007/s13679-017-0256-9

150

Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. Longo DL, ed. N Engl J Med. 2017;376(3):254-266. https://doi.org/10.1056/NEJMra1514009

151

Guh DP, Zhang W, Bansback N, et al. The incidence of comorbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9:88. https://doi.org/10.1186/1471-2458-9-88

152

Lenz M, Richter T, Mühlhauser I. The Morbidity and Mortality Associated With Overweight and Obesity in Adulthood. Dtsch Aerzteblatt Online. 2009;106:641-648. doi: https://doi.org/10.3238/arztebl.2009.0641

153

Cardoso L, Rodrigues D, Gomes L, Carrilho F. Short- and long-term mortality after bariatric surgery: A systematic review and meta-analysis. Diabetes Obes Metab 2017;19:1223-1232. https://doi.org/10.1111/dom.12922

154

Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003;290:86-97. https://doi.org/10.1001/jama.290.1.86

155

Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142:233-239. https://doi.org/10.7326/0003-4819-142-4-200502150-00005

156

Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018;5:CD000146. https://doi.org/10.1002/14651858.cd000146.pub5

157

Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007:CD000031. https://doi.org/10.1002/14651858.cd000031.pub4

158

Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016:CD006103. https://doi.org/10.1002/14651858.cd006103.pub7

159

Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2019;4:CD013308. https://doi.org/10.1002/14651858.cd013308

160

Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012;110:968-970. https://doi.org/10.1016/j.amjcard.2012.05.028

161

Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert C, Madan M, Abramson BL, Dehghani P, EVITA Investigators. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. Circulation 2016;133:21-30. https://doi.org/10.1161/circulationaha.115.019634

162

Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med 2018;178:622-631. https://doi.org/10.1001/jamainternmed.2018.0397

163

Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, Joseph L, Reynier PM, Filion KB. Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Qual Outcomes 2017;10:e002458. https://doi.org/10.1161/circoutcomes.115.002458

164

Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med 2018;379:623-632. https://doi.org/10.1056/nejmoa1803626

165

Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, et al. Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:1513-1523. https://doi.org/10.1016/s0140-6736(18)30134-x

166

Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, Bennett DA, Chen Y, Dong C, Hu R, Zhou G, Yu B, Jia W, Parish S, Clarke R, Davey Smith G, Collins R, Holmes MV, Li L, Peto R, Chen Z, China Kadoorie Biobank Collaborative Group. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. Lancet 2019;393:1831-1842. http://doi.org/10.1016/S0140-6736(18)31772-0

167

Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, Prieto-Merino D, Dehghan A, Trompet S, Wong A, Cavadino A, Drogan D, et al. InterAct Consortium. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014;349:g4164. https://doi.org/10.1136/bmj.g4164

168

Albus C, Waller C, Fritzsche K, Gunold H, Haass M, Hamann B, Kindermann I, Kollner V, Leithauser B, Marx N, Meesmann M, Michal M, Ronel J, Scherer M, Schrader V, Schwaab B, Weber CS, Herrmann-Lingen C. Significance of psycho-social factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol 2019;108:1175-1196. https://doi.org/10.1007/s00392-019-01488-w

169

Vaccarino V, Badimon L, Bremner JD, Cenko E, Cubedo J, Dorobantu M, Duncker DJ, Koller A, Manfrini O, Milicic D, Padro T, Pries AR, Quyyumi AA, Tousoulis D, Trifunovic D, Vasiljevic Z, de Wit C, Bugiardini R, ESC Scientific Document Group Reviewers. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. Eur Heart J 2020;41:1687-1696. https://doi.org/10.1093/eurheartj/ehy913

170

Petersen BD, Stenager E, Mogensen CB, Erlangsen A. The association between heart diseases and suicide: a nationwide cohort study. J Intern Med 2020;287:558-568. https://doi.org/10.1111/joim.13025

171

Albert MA, Glynn RJ, Buring J, Ridker PM. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006;114:2619-2626. https://doi.org/10.1161/circulationaha.106.660043

172

Alter DA, Franklin B, Ko DT, Austin PC, Lee DS, Oh PI, Stukel TA, Tu JV. Socioeconomicstatus, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One 2013;8(6):e65130. https://doi.org/10.1371/journal.pone.0065130

173

Berntson J, Patel JS, Stewart JC. Number of recent stressful life events and incident cardiovascular disease: Moderation by lifetime depressive disorder. J Psychosom Res 2017; 99: 149-154. https://doi.org/10.1016/j.jpsychores.2017.06.008. Epub 2017 Jun 12.

174

Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Hofer S, Doyle F, Schmid JP, von Kanel R. Psychosocial aspects in cardiac rehabilitation: from theoryto practice. A position paper from the Cardiac Rehabilitation Section of the EuropeanAssociation of Cardiovascular Prevention and Rehabilitation of the EuropeanSociety of Cardiology. Eur J Prev Cardiol 2015;22:1290-1306. https://doi.org/10.1177/2047487314543075

175

Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: A metaanalysis. Psychosom Med 2010;72:563-569. https://doi.org/10.1097/psy.0b013e3181dbff97

176

Smoller JW, Pollack MH, Wassertheil-Smoller S, Jackson RD, ObermanA,Wong ND, Sheps D. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women’s Health Initiative Observational Study. Arch Gen Psychiatry 2007;64:1153-1160. https://doi.org/10.1001/archpsyc.64.10.1153

177

Albus C, Jordan J, Herrmann-Lingen C. Screening for psychosocial risk factors in patients with coronary heart disease-recommendations for clinical practice. Eur J Cardiovasc Prev Rehabil 2004;11:75-79. https://doi.org/10.1097/01.hjr.0000116823.84388.6c

178

Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011;171:134-140. https://doi.org/10.1001/archinternmed.2010.510

179

Orth-Gomer K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes 2009;2(1):25-32. https://doi.org/10.1161/circoutcomes.108.812859

180

Dickens C, Cherryington A, Adeyemi I, Roughley K, Bower P, Garrett C, Bundy C, Coventry P. Characteristics of psychological interventions that improve depression in people with coronary heart disease: a systematic review and meta-regression. Psychosom Med 2013;75(2):211-221. https://doi.org/10.1097/psy.0b013e31827ac009

181

Бойцов С.А., Погосова Н.В., Бубнова М.Г., Драпкина О.М. и соавт. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российское кардиологическое общество, Национальное общество профилактической кардиологии, Российское общество профилактики неинфекционных заболеваний. Российский кардиологический журнал. 2018;23(6):7-122. http://dx.doi.org/10.15829/1560-4071-2018-6-7-122

Boytsov S.A., Pogosova N.V., Bubnova M.G., Drapkina O.M. et al. Cardiovascular Prevention 2017. National Guidelines. Russian Journal of Cardiology. 2018;(6):7-122. (In Russ.). http://dx.doi.org/10.15829/1560-4071-2018-6-7-122

182

Blumenthal JA, Sherwood A, Smith PJ, Watkins L, Mabe S, Kraus WE, Ingle K, Miller P, Hinderliter A. Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. Circulation 2016;133:1341-1350. https://doi.org/10.1161/circulationaha.115.018926

183

He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev 2020;25:919-926. https://doi.org/10.1007/s10741-019-09850-w

184

Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, Prettin C, Gottwik M, Bohm M, Faller H, Deckert J, Ertl G, MOOD-HF Study Investigators and Committee Members. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA 2016;315:2683-2693. https://doi.org/10.1001/jama.2016.7635

185

Michael J Sateia, International Classification of Sleep Disorders-Third Edition, Chest, 2014 Nov;146(5):1387-1394, ISSN 0012-3692, https://doi.org/10.1378/chest.14-0970

186

Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep. 1999 Aug 1;22(5):667-89. PMID: 10450601.

187

Young T, Palta M, Dempsey J, et al. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. Wis- consin Medical J. 2009;108(5):246-9. PMID: 19743755

188

Lopez PP, Stefan B, Schulman CI, et al. Prevalence of sleep apnea in morbidly obese patients who presented for weight loss surgery evaluation: more evidence for routine screening for obstructive sleep apnea before weight loss surgery. Am Surg 2008;74:834-8. PMID: 18807673

189

Peppard PE, Ward NR, Morrell MJ. The impact of obesity on oxygen desaturation during sleep-disordered breathing. Am J Respir Crit Care Med 2009;180:788-793. https://doi.org/10.1164/rccm.200905-0773oc

190

Redline S, Schluchter MD, Larkin EK, Tishler PV. Predictors of longitudinal change in sleep-disordered breathing in a nonclinic population. Sleep 2003;26:703-70. https://doi.org/10.1093/sleep/26.6.703

191

Yeghiazarians Y, Jneid H, Tietjens JR, Redline S, Brown DL, El-Sherif N, Mehra R, Bozkurt B, Ndumele CE, Somers VK. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-e67. doi: 10.1161/CIR.0000000000000988. Epub 2021 Jun 21. Erratum in: Circulation. 2022 Mar 22;145(12):e775. PMID: 34148375. https://doi.org/10.1161/cir.0000000000000988

192

Leinum CJ, Dopp JM, Morgan BJ. Sleep-disordered breathing and obesity: pathophysiology, complications, and treatment. Nutr Clin Pract. 2009 Dec;24(6):675-87. PMID: 19955545; PMCID: PMC2873205. https://doi.org/10.1177/0884533609351532

193

Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, Harrod CG. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479-504. https://doi.org/10.5664/jcsm.6506

194

Hudgel DW, Patel SR, Ahasic AM, Bartlett SJ, Bessesen DH, Coaker MA, Fiander PM, Grunstein RR, Gurubhagavatula I, Kapur VK, Lettieri CJ, Naughton MT, Owens RL, Pepin JL, Tuomilehto H, Wilson KC; American Thoracic Society Assembly on Sleep and Respiratory Neurobiology. The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Sep 15;198(6):e70-e87. PMID: 30215551. https://doi.org/10.1164/rccm.201807-1326ST

195

Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014 Feb 22;383(9918):736-47. doi: 10.1016/S0140-6736(13)60734-5. Epub 2013 Aug 2. PMID: 23910433; PMCID: PMC3909558.

196

Jonas DE, Amick HR, Feltner C, Weber RP, Arvanitis M, Stine A, Lux L, Harris RP Screening for Obstructive Sleep Apnea in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017;317(4):415. PMID: 28211654

197

Giles TL, Lasserson TJ, Smith BJ, White J, Wright J, Cates CJ Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001106. https://doi.org/10.1002/14651858.cd001106.pub2

198

Walia HK, Thompson NR, Pascoe M, Faisal M, Moul DE, Katzan I, Mehra R, Foldvary-Schaefer N Effect of Positive Airway Pressure Therapy on Drowsy Driving in a Large Clinic-Based Obstructive Sleep Apnea Cohort. J Clin Sleep Med. 2019;15(11):1613-1620. https://doi.org/10.5664/jcsm.8024

199

Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2019;15(2):335-343. https://doi.org/10.5664/jcsm.7640

200

Аксенова А.В., Сивакова О.А., Блинова Н.В., Данилов Н.М. и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии по диагностике и лечению резистентной артериальной гипертонии. Терапевтический архив. 2021;93(9):1018-1029. https://doi.org/10.26442/00403660.2021.09.201007

Aksenova A.V., Sivakova O.A., Blinova N.V., Danilov N.M., et al. Russian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management. Terapevticheskii arkhiv. 2021;93(9):1018-1029 (In Russ.). https://doi.org/10.26442/00403660.2021.09.201007

201

Mokhlesi B, Masa JF, Brozek JL, Gurubhagavatula I, et al. Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 Aug 1;200(3):e6-e24. Erratum in: Am J Respir Crit Care Med. 2019 Nov 15;200(10):1326. PMID: 31368798; PMCID: PMC6680300. https://doi.org/10.1164/rccm.201905-1071ST

202

Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS, Gaudio JC, Taylor MR, Zwillich CW. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004 Jan 1;116(1):1-7. https://doi.org/10.1016/j.amjmed.2003.08.022 PMID: 14706658.

203

Mokhlesi B. Obesity hypoventilation syndrome: a state-of-the-art review. Respir Care. 2010 Oct;55(10):1347-62; discussion 1363-5. PMID: 20875161

204

Chau EH, Lam D, Wong J, Mokhlesi B, Chung F, Obesity hypoventilation syndrome: a review of epidemiology, pathophysiology, and perioperative considerations, Anesthesiology. 2012 Jul;117(1):188-205. https://doi.org/10.1097/aln.0b013e31825add60

205

Lecube A, Sampol G, Lloberes P, Romero O, Mesa J, Morell F, SimóR, Asymptomatic sleep-disordered breathing in premenopausal women awaiting bariatric surgery. Obes Surg. 2010 Apr;20(4):454-61. Epub 2009 Dec 18. https://doi.org/10.1007/s11695-009-0033-2

206

Domínguez-Cherit G, Gonzalez R, Borunda D, Pedroza J, Gonzalez-Barranco J, Herrera MF, Anesthesia for morbidly obese patients. World J Surg. 1998;22(9):969. https://doi.org/10.1007/s002689900501

207

Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS, Gaudio JC, Taylor MR, Zwillich CW. Obesity-associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med. 2004;116(1):1. https://doi.org/10.1016/j.amjmed.2003.08.022

208

Шарипова Г.М. Особенности поражения органов-мишеней у больных артериальной гипертонией в зависимости от наличия и отсутствия метаболического синдрома. Дисс. д.м.н., М., 2009.

Sharipova G.M. Features of target organ damage in patients with arterial hypertension depending on the presence and absence of metabolic syndrome. Diss. MD, M., 2009 (In Russ.).

209

Жернакова Ю.В. Клиническая характеристика различных вариантов течения метаболического синдрома и возможности влияния антигипертензивной терапии на уровень артериального давления, состояние углеводного, липидного обменов и выраженность ожирения у больных артериальной гипертонией и метаболическим синдромом. Дисс. д.м.н., М., 2012.

Zhernakova Yu.V. Clinical characteristics of various variants of the course of the metabolic syndrome and the possibility of the effect of antihypertensive therapy on the level of blood pressure, the state of carbohydrate and lipid metabolism and the severity of obesity in patients with arterial hypertension and metabolic syndrome. Diss. MD, M., 2012 (In Russ.).

210

И. Е. Чазова, Ю.В. Жернакова от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16(1): 6-31.

Chazova I.E., Zhernakova Yu.V. Diagnosis and treatment of arterial hypertension [Guidelines]. Systemic hypertensions. 2019; 16(1): 6-31. (In Russ.).

211

De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis 2008; 50:238–263. https://doi.org/10.1016/j.pcad.2007.08.001

212

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual datafor one million adults in 61 prospective studies. Lancet 2002; 360:1903–1913. https://doi.org/10.1016/s0140-6736(02)11911-8

213

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017;35:922–944. https://doi.org/10.1097/hjh.0000000000001276

214

D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743–753. https://doi.org/10.1161/circulationaha.107.699579

215

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33:1635–1701. https://doi.org/10.1093/eurheartj/ehs092

216

Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B, Blood Pressure-Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184–191. https://doi.org/10.7326/m14-0773

217

Brunstrom M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med 2018;178:28–36. https://doi.org/10.1001/jamainternmed.2017.6015

218

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290–300. https://doi.org/10.1016/j.amjmed.2008.09.038

219

MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P, Mackenzie IS, Padmanabhan S, McCann GP, Salsbury J, McInnes G, Brown MJ, British Hypertension Society Programme of Prevention And Treatment of Hypertension With Algorithm-based Therapy (PATHWAY). Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017;6:e006986. https://doi.org/10.1161/jaha.117.006986

220

Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens 2016;34:1921-1932. https://doi.org/10.1097/hjh.0000000000001052

221

Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Diaz R, Dans A, Dagenais G, HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374: 2032-2043. https://doi.org/10.1056/nejmoa1600177

222

Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26:819-824. https://doi.org/10.1097/hjh.0b013e3282f4edd7

223

Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407. https://doi.org/10.1161/hypertensionaha.109.139816

224

Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ III, Graff A, Shojaee A, Waverczak WF, Qian C, Jones CJ, Neutel JM. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011;13:404–412. https://doi.org/10.1111/j.1751-7176.2011.00437.x

225

Volpe M, Christian Rump L, Ammentorp B, Laeis P. Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. Clin Drug Investig 2012;32:649-664. https://doi.org/10.1007/bf03261919

226

Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, Ford I, Cruickshank JK, Caulfield MJ, Salsbury J, Mackenzie I, Padmanabhan S, Brown MJ, British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-2068. https://doi.org/10.1016/s0140-6736(15)00257-3

227

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957-967. https://doi.org/10.1016/s0140-6736(15)01225-8

228

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015;33:1321-1341. https://doi.org/10.1097/hjh.0000000000000614

229

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 2016;34:613-622. https://doi.org/10.1097/hjh.0000000000000881

230

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels–overview and meta-analyses of randomized trials. J Hypertens 2014;32:2296-2304. https://doi.org/10.1097/hjh.0000000000000379

231

Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39:3021-3104. https://doi.org/10.1093/eurheartj/ehy339

232

Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016;387:435-443. https://doi.org/10.1016/s0140-6736(15)00805-3

233

Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389(10085):2226-2237. https://doi.org/10.1016/S0140-6736(17)30754-7

234

Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Press. 2016;25(2):83-92. https://doi.org/10.3109/08037051.2015.1106750

235

Mancia G, Kjeldsen SE, Zappe DH, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37(12):955-964. https://doi.org/10.1093/eurheartj/ehv633

236

SPRINT Research Group, et al. A Randomized Trial of Intensive versus Standard BloodPressure Control. N Engl J Med. 2015;373(22):2103-2116. https://doi.org/10.1056/NEJMoa1511939

237

Tsai W-C, Wu H-Y, Peng Y-S, et al. Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease. JAMA Intern Med. 2017;177(6):792. https://doi.org/10.1001/jamainternmed.2017.0197

238

Jafar TH, Stark PC, Schmid CH, et al. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis. Ann Intern Med. 2003;139(4):244. https://doi.org/10.7326/0003-4819-139-4-200308190-00006

239

Sim JJ, Shi J, Kovesdy CP, et al. Impact of Achieved Blood Pressures on Mortality Risk and End-Stage Renal Disease Among a Large, Diverse Hypertension Population. J Am Coll Cardiol. 2014;64(6):588- 597. https://doi.org/10.1016/j.jacc.2014.04.065

240

Owen JG, Reisin E. Anti-hypertensive Drug Treatment of Patients with and the Metabolic Syndrome and Obesity: a Review of Evidence, Meta-Analysis, Post hoc and Guidelines Publications. Curr Hypertens Rep. 2015;17(6):46. https://doi.org/10.1007/s11906-015-0558-9

241

Tocci G, Paneni F, Palano F, et al. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A MetaAnalysis of Placebo-Controlled Clinical Trials. Am J Hypertens. 2011;24(5):582-590. https://doi.org/10.1038/ajh.2011.8

242

Abuissa H, Jones PG, Marso SP, O’Keefe JH. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes. J Am Coll Cardiol. 2005;46(5):821-826. https://doi.org/10.1016/j.jacc.2005.05.051

243

Yang Y, Wei R, Xing Y, et al. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients. Metabolism. 2013;62(12):1858-1866. https://doi.org/10.1016/j.metabol.2013.08.008

244

NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477-1490. https://doi.org/10.1056/nejmoa1001121

245

Скибицкий В.В. и др. Антигипертензивные и вазопротективные эффекты комбинированной фармакотерапии у пациентов с артериальной гипертензией и предиабетом. Кардиология, 2020;60(4). https://doi.org/10.18087/cardio.2020.4.n1112

Skibitsky V.V. Antihypertensive and vasoprotective effects of combined pharmacotherapy in patients with arterial hypertension and prediabetes. Cardiology, 2020;60(4). (In Russ.). https://doi.org/10.18087/cardio.2020.4.n1112

246

Abellán J et al. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients. Kidney Int Suppl. 2005, Jan;(93):S20-4. https://doi.org/10.1111/j.1523-1755.2005.09305.x

247

Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens 2004 Sep; 18 (9): 669-75. https://doi.org/10.1038/sj.jhh.1001676

248

McGill H. Fatty streaks in the coronary arteries and aorta. Lab Invest. 1968;560-4. PMID: 5681198

249

Strong JP, Malcom GT, McMahan CA, Tracy RE, Newman III WP, Herderick EE, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. Jama. 1999;281(8):727-35. https://doi.org/10.1001/jama.281.8.727

250

McGill Jr HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105(23):2712-8. https://doi.org/10.1161/01.cir.0000018121.67607.ce

251

Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338(23):1650-6. https://doi.org/10.1056/nejm199806043382302

252

McGill Jr HC, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 1995;15(4):431-40. https://doi.org/10.1161/01.atv.15.4.431

253

Zieske AW, Malcom GT, Strong JP. Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. Pediatr Pathol Mol Med. 2002;21(2):213-37. https://doi.org/10.1080/15227950252852104

254

Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399-409. https://doi.org/10.1038/nrcardio.2009.55

255

Ross R. Pathogenesis of atherosclerosis-atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(5):S419. https://doi.org/10.1016/s0002-8703(99)70266-8

256

Couillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P, et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab. 2005;90(12):6454–9. https://doi.org/10.1210/jc.2004-2438

257

Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364–73. https://doi.org/10.1016/j.tcm.2015.10.004

258

Engin A. Endothelial dysfunction in obesity. Obes lipotoxicity. 2017;345–79. https://doi.org/10.1007/978-3-319-48382-5_15

259

Calle EE, Thun MJ, Petrelli JM, Rodriguez C. Health, CW Jr. Body-mass index Mortal a Prospect cohort US adults. 1994;1097–104.

260

Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968–77. https://doi.org/10.1161/01.cir.67.5.968

261

Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Engl J Med. 1995;333(11):677–85.

262

Folsom AR, Stevens J, Schreiner PJ, McGovern PG, Investigators AR in CS. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Am J Epidemiol. 1998;148(12):1187–94.

263

Bogers RP, Bemelmans WJE, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167(16):1720–8.

264

Romero-Corral A, Somers VK, Sierra-Johnson J, Korenfeld Y, Boarin S, Korinek J, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010;31(6):737–46.

265

Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, et al. Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med. 2015;163(11):827–35.

266

Coutinho T, Goel K, Corrêa de Sá D, Carter RE, Hodge DO, Kragelund C, et al. Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of “normal weight central obesity.” J Am Coll Cardiol. 2013;61(5):553–60.

267

Canoy D, Cairns BJ, Balkwill A, Wright FL, Green J, Reeves G, et al. Coronary heart disease incidence in women by waist circumference within categories of body mass index. Eur J Prev Cardiol. 2013;20(5):759–62.

268

Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, et al. Obesity and subtypes of incident cardiovascular disease. J Am Heart Assoc. 2016;5(8):e003921.

269

Wilson PWF, Bozeman SR, Burton TM, Hoaglin DC, Ben-Joseph R, Pashos CL. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation. 2008;118(2):124–30.

270

Mørkedal B, Vatten LJ, Romundstad PR, Laugsand LE, Janszky I. Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. J Am Coll Cardiol. 2014;63(11):1071–8.

271

Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med. 2014;174(1):15–22.

272

Lassale C, Tzoulaki I, Moons KGM, Sweeting M, Boer J, Johnson L, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J. 2018;39(5):397–406.

273

Lu Y, Hajifathalian K, Ezzati M, Woodward M, Rimm EB, Danaei G. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective coh. Lancet. 2014;383(9921):970–83.

274

Himabukuro M, Hirata Y, Tabata M, Dagvasumberel M, Sato H, Kurobe H, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33(5):1077–84.

275

Ishii T, Asuwa N, Masuda S, Ishikawa Y. The effects of a myocardial bridge on coronary atherosclerosis and ischaemia. J Pathol A J Pathol Soc Gt Britain Irel. 1998;185(1):4–9.

276

Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging. 2010;3(6):623–40.

277

Taqueti VR, Di Carli MF. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72(21):2625–41.

278

Lee B-K, Lim H-S, Fearon WF, Yong AS, Yamada R, Tanaka S, et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015;131(12):1054–60.

279

Taqueti VR, Hachamovitch R, Murthy VL, Naya M, Foster CR, Hainer J, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131(1):19–27.

280

Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang X-L, et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol. 2006;47(6):1188–95.

281

Bajaj NS, Osborne MT, Gupta A, Tavakkoli A, Bravo PE, Vita T, et al. Coronary microvascular dysfunction and cardiovascular risk in obese patients. J Am Coll Cardiol. 2018;72(7):707–17.

282

Quercioli A, Montecucco F, Pataky Z, Thomas A, Ambrosio G, Staub C, et al. Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. Eur Heart J. 2013;34(27):2063–73.

283

Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–1010.

284

Snelder SM, van de Poll SWE, de Groot–de Laat LE, Kardys I, Zijlstra F, van Dalen BM. Optimized electrocardiographic criteria for the detection of left ventricular hypertrophy in obesity patients. Clin Cardiol. 2020;43(5):483–90.

285

Peguero JG, Lo Presti S, Perez J, Issa O, Brenes JC, Tolentino A. Electrocardiographic criteria for the diagnosis of left ventricular hypertrophy. J Am Coll Cardiol. 2017;69(13):1694–703.

286

Karason K, Lindroos AK, Stenlöf K, Sjöström L. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. Arch Intern Med. 2000;160(12):1797–802.

287

Chrysohoou C, Skoumas J, Georgiopoulos G, Liontou C, Vogiatzi G, Tsioufis K, et al. Exercise capacity and haemodynamic response among 12,327 individuals with cardio-metabolic risk factors undergoing treadmill exercise. Eur J Prev Cardiol. 2017;24(15):1627–36.

288

Bires AM, Lawson D, Wasser TE, Raber-Baer D. Comparison of Bruce treadmill exercise test protocols: is ramped Bruce equal or superior to standard bruce in producing clinically valid studies for patients presenting for evaluation of cardiac ischemia or arrhythmia with body mass index equal to or grea. J Nucl Med Technol. 2013;41(4):274–8.

289

Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018;3(4):280–7.

290

Elagizi A, Kachur S, Lavie CJ, Carbone S, Pandey A, Ortega FB, et al. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog Cardiovasc Dis[Internet].2018;61(2):142–50. Available from: https://www.sciencedirect.com/science/article/pii/S0033062018301300

291

Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2018;61(2):151–6.

292

Bassi N, Karagodin I, Wang S, Vassallo P, Priyanath A, Massaro E, et al. Lifestyle modification for metabolic syndrome: a systematic review. Am J Med. 2014;127(12):1242-e1.

293

Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein AC, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50(4):609–16.

294

Group LAR. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.

295

Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. bmj. 2017;359.

296

Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Thomas RJ, Squires RW, et al. Prognostic importance of weight loss in patients with coronary heart disease regardless of initial body mass index. Eur J Prev Cardiol. 2008;15(3):336–40.

297

Batsis JA, Sarr MG, Collazo-Clavell ML, Thomas RJ, Romero-Corral A, Somers VK, et al. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol. 2008;102(7):930–7.

298

Payvar S, Kim S, Rao S V, Krone R, Neely M, Paladugu N, et al. In-hospital outcomes of percutaneous coronary interventions in extremely obese and normal-weight patients: findings from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2013;62(8):692–6.

299

Joncas SX, Poirier P, Ardilouze J, Carrier N, Fayad T, Farand P. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome. Obesity. 2013;21(9):1753–8.

300

Buschur ME, Smith D, Share D, Campbell W, Mattichak S, Sharma M, et al. The burgeoning epidemic of morbid obesity in patients undergoing percutaneous coronary intervention: insight from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J Am Coll Cardiol. 2013;62(8):685–91.

301

Holroyd EW, Sirker A, Kwok CS, Kontopantelis E, Ludman PF, De Belder MA, et al. The relationship of body mass index to percutaneous coronary intervention outcomes: does the obesity paradox exist in contemporary percutaneous coronary intervention cohorts? Insights from the British Cardiovascular Intervention Society Registry. JACC Cardiovasc Interv. 2017;10(13):1283–92.

302

Terada T, Forhan M, Norris CM, Qiu W, Padwal R, Sharma AM, et al. Differences in short‐and long‐term mortality associated with BMI following coronary revascularization. J Am Heart Assoc. 2017;6(4):e005335.

303

Lancefield T, Clark DJ, Andrianopoulos N, Brennan AL, Reid CM, Johns J, et al. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv. 2010;3(6):660–8.

304

Mehta L, Devlin W, McCullough PA, O’Neill WW, Skelding KA, Stone GW, et al. Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol. 2007;99(7):906–10.

305

Park D-W, Kim Y-H, Yun S-C, Ahn J-M, Lee J-Y, Kim W-J, et al. Association of body mass index with major cardiovascular events and with mortality after percutaneous coronary intervention. Circ Cardiovasc Interv. 2013;6(2):146–53.

306

Ma W, Sun X, Wang Y, Han X, Zhu Y, Liu N. Does body mass index truly affect mortality and cardiovascular outcomes in patients after coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft? A systematic review and network meta‐analysis. Obes Rev. 2018;19(9):1236–47.

307

Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR, Yuksel F, et al. The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people. Clin Med Res. 2010;8(2):89–95.

308

Beavers CJ, Heron P, Smyth SS, Bain JA, Macaulay TE. Obesity and antiplatelets-does one size fit all? Thromb Res. 2015;136(4):712–6.

309

Farb MG, Bigornia S, Mott M, Tanriverdi K, Morin KM, Freedman JE, et al. Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. J Am Coll Cardiol. 2011;58(3):232–7.

310

Neergaard-Petersen S, Hvas A-M, Kristensen SD, Grove EL. Platelets and antiplatelet therapy in patients with coronary artery disease and diabetes. In: Seminars in thrombosis and hemostasis. Thieme Medical Publishers; 2016. p. 234–41.

311

Prabhakar G, Haan CK, Peterson ED, Coombs LP, Cruzzavala JL, Murray GF. The risks of moderate and extreme obesity for coronary artery bypass grafting outcomes: a study from the Society of Thoracic Surgeons’ database. Ann Thorac Surg. 2002;74(4):1125–31.

312

Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Obesity is not a risk factor for significant adverse outcomes after cardiac surgery. Circulation. 1996;94(9 Suppl):II87-92.

313

Birkmeyer NJO, Charlesworth DC, Hernandez F, Leavitt BJ, Marrin CAS, Morton JR, et al. Obesity and risk of adverse outcomes associated with coronary artery bypass surgery. Circulation. 1998;97(17):1689–94.

314

Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar‐Zadeh K. Effect of obesity on short‐and long‐term mortality postcoronary revascularization: a meta‐analysis. Obesity. 2008;16(2):442–50.

315

Wagner BD, Grunwald GK, Rumsfeld JS, Hill JO, Ho PM, Wyatt HR, et al. Relationship of body mass index with outcomes after coronary artery bypass graft surgery. Ann Thorac Surg. 2007;84(1):10–6.

316

Ruka E, Dagenais F, Mohammadi S, Chauvette V, Poirier P, Voisine P. Bilateral mammary artery grafting increases postoperative mediastinitis without survival benefit in obese patients. Eur J Cardio-Thoracic Surg. 2016;50(6):1188–95.

317

Donna K. Arnett, Roger S. Blumenthal, Michelle A. Albert, Andrew B. Buroker, Zachary D. Goldberger, Ellen J. Hahn, Cheryl Dennison Himmelfarb, Amit Khera, Donald Lloyd-Jones, J. William McEvoy, Erin D. Michos, Michael D. Miedema, Daniel Muñoz, Sidney C. Smith, Salim S. Virani, Kim A. Williams, Joseph Yeboah, Boback Ziaeian, 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, JACC, Volume 74, Issue 10, 2019, pp. e177-e232, https://doi.org/10.1016/j.jacc.2019.03.010.

318

Juhani Knuuti, William Wijns, Antti Saraste, Davide Capodanno, Emanuele Barbato, Christian Funck-Brentano, Eva Prescott, Robert F Storey, Christi Deaton, Thomas Cuisset, Stefan Agewall, Kenneth Dickstein, Thor Edvardsen, Javier Escaned, Bernard J Gersh, Pavel Svitil, Martine Gilard, David Hasdai, Robert Hatala, Felix Mahfoud, Josep Masip, Claudio Muneretto, Marco Valgimigli, Stephan Achenbach, Jeroen J Bax, ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC), European Heart Journal, Volume 41, Issue 3, 14 January 2020, Pages 407–477, https://doi.org/10.1093/eurheartj/ehz425

319

Joseph, J., Velasco, A., Hage, F.G. and Reyes, E., 2018. Guidelines in review: Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. Journal of Nuclear Cardiology, 25(2), pp.509-515.

320

Martin, S.S., Blaha, M.J., Blankstein, R., Agatston, A., Rivera, J.J., Virani, S.S., Ouyang, P., Jones, S.R., Blumenthal, R.S., Budoff, M.J. and Nasir, K., 2014. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation, 129(1), pp.77-86.

321

Kim NH, Han KH, Choi J, Lee J, Kim SG. Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. BMJ. 2019 Sep 27;366:l5125. https://doi.org/10.1136/bmj.l5125, PMID: 31562117; PMCID: PMC6763755.

322

Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и Дислипидемии. 2020;38(1):7-42.

Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision. atherosclerosis and dyslipidemia. 2020;38(1):7-42. (In Russ.).

323

Pathak RK, Mahajan R, Lau DH, Sanders P. The implications of obesity for cardiac arrhythmia mechanisms and management. Can J Cardiol. 2015;31:203-210. https://doi.org/10.1016/j.cjca.2014.10.027

324

Plourde B, Sarrazin JF, Nault I, Poirier P Sudden cardiac death and obesity. Expert Rev Cardiovasc Ther. 2014;12:1099-1110. https://doi.org/10.1586/14779072.2014

325

Chiuve SE, Sun Q, Sandhu RK, Tedrow U, Cook NR, Manson JE, Albert CM. Adiposity throughout adulthood and risk of sudden cardiac death in women. JACC Clin Electrophysiol. 2015;1:520-528. https://doi.org/10.1016/j.jacep.2015.07.011

326

Adabag S, Huxley RR, Lopez FL, Chen LY, Sotoodehnia N, Siscovick D, Deo R, Konety S, Alonso A, Folsom AR. Obesity related risk of sudden cardiac death in the Atherosclerosis Risk in Communities study. Heart. 2015;101:215-221. https://doi.org/10.1136/heartjnl-2014-306238

327

Aune D, Schlesinger S, Norat T, Riboli E. Body mass index, abdominal fatness, and the risk of sudden cardiac death: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33:711-722. https://doi.org/10.1007/s10654-017-0353-9

328

Hookana E, Junttila MJ, Puurunen VP, Tikkanen JT, Kaikkonen KS, Kortelainen ML, Myerburg RJ, Huikuri HV. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm. 2011;8:1570-1 575. https://doi.org/10.1016/j.hrthm.2011.06.031

329

Empana JP, Ducimetiere P, Charles MA, Jouven X. Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I. Circulation. 2004;110:2781-2785. https://doi.org/10.1161/01.CIR.0000146395.64065.BA

330

Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death: increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med. 1987;147:1725-1728. https://doi.org/10.1001/archinte.147.10.1725

331

Fraley MA, Birchem JA, Senkottaiyan N, Alpert MA. Obesity and the electrocardiogram. Obes Rev. 2005;6:275-281. https://doi.org/10.1111/j.1467-789X.2005.00199.x

332

Pietrasik G, Goldenberg I, McNitt S, Moss AJ, Zareba W. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients. J Cardiovasc Electrophysiol. 2007;18:181-184. https://doi.org/10.1111/j.1540-8167.2006.00680.x

333

Sabbag A, Goldenberg I, Moss AJ, McNitt S, Glikson M, Biton Y, Jackson L, Polonsky B, Zareba W, Kutyifa V. Predictors and risk of ventricular tachyarrhythmias or death in Black and White cardiac patients: a MADIT-CRT Trial substudy. JACC Clin Electrophysiol. 2016;2:448-455. https://doi.org/10.1016/j.jacep.2016.03.003

334

Lalani AP, Kanna B, John J, Ferrick KJ, Huber MS, Shapiro LE. Abnormal signal-averaged electrocardiogram (SAECG) in obesity. Obes Res. 2000;8:20-28. https://doi.org/10.1038/oby.2000

335

Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70:921-924. https://doi.org/10.1016/0002-9149(92)90739-l

336

Duflou J, Virmani R, Rabin I, Burke A, Farb A, Smialek J. Sudden death as a result of heart disease in morbid obesity. Am Heart J. 1995;130:306-313. https://doi.org/10.1016/0002-8703(95)90445-x

337

Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol. 2011;57:1368-1374. https://doi.org/10.1016/j.jacc.2010.10.042

338

Konno T, Hayashi K, Fujino N, Oka R, Nomura A, Nagata Y, Hodatsu A, Sakata K, Furusho H, Takamura M, et al. Electrocardiographic QRS fragmentation as a marker for myocardial fibrosis in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26:1081-1087. https://doi.org/10.1111/jce.12742

339

Narayanan K, Zhang L, Kim C, Uy-Evanado A, Teodorescu C, Reinier K, Zheng ZJ, Gunson K, Jui J, Chugh SS. QRS fragmentation and sudden cardiac death in the obese and overweight. J Am Heart Assoc. 2015;4:e001654. https://doi.org/10.1161/JAHA.114.001654

340

Brenyo A, Pietrasik G, Barsheshet A, Huang DT, Polonsky B, McNitt S, Moss AJ, Zareba W. QRS fragmentation and the risk of sudden cardiac death in MADIT II. J Cardiovasc Electrophysiol. 2012;23:1343-1348. https://doi.org/10.1111/j.1540-8167.2012.02390.x

341

Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896-908. https://doi.org/10.1001/jama.2013

342

Wu CK, Tsai HY, Su MY, Wu YF, Hwang JJ, Tseng WY, Lin JL, Lin LY. Pericardial fat is associated with ventricular tachyarrhythmia and mortality in patients with systolic heart failure. Atherosclerosis. 2015;241:607-614. https://doi.org/10.1016/j.atherosclerosis.2015.05.025

343

Fuller B, Garland J, Anne S, Beh R, McNevin D, Tse R. Increased epicardial fat thickness in sudden death from stable coronary artery atherosclerosis. Am J Forensic Med Pathol. 2017;38:162-166. https://doi.org/10.1097/PAF.0000000000000310

344

Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, O’Donnell CJ, Fox CS, Hoffmann U. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30:850-856. https://doi.org/10.1093/eurheartj/ehn573

345

Shah RV, Anderson A, Ding JZ, Budoff M, Rider O, Petersen SE, Jensen MK, Koch M, Allison M, Kawel-Boehm N, et al. Pericardial, but not hepatic, fat by CT Is Associated With cv outcomes and structure: the Multi-Ethnic Study of Atherosclerosis. JACC Cardiovasc Imag. 2017;10:1016-1027. https://doi.org/10.1016/j.jcmg.2016.10.024

346

Chi PC, Chang SC, Yun CH, Kuo JY, Hung CL, Hou CJ, Liu CY, Yang FS, Wu TH, Bezerra HG, et al. The associations between various ectopic visceral adiposity and body surface electrocardiographic alterations: potential differences between local and remote systemic effects. PLoS One. 2016;11:e0158300. https://doi.org/10.1371/journal.pone.0158300

347

Cheng VY, Dey D, Tamarappoo B, Nakazato R, Gransar H, Miranda-Peats R, Ramesh A, Wong ND, Shaw LJ, Slomka PJ, et al. Pericardial fat burden on ECG-gated noncontrast CT in asymptomatic patients who subsequently experience adverse cardiovascular events. JACC Cardiovasc Imaging. 2010;3:352-360. https://doi.org/10.1016/j.jcmg.2009.12.013

348

Al-Mosawi AA, Nafakhi H, Hassan MB, Alareedh M, Al-Nafakh HA. ECG markers of arrythmogenic risk relationships with pericardial fat volume and BMI in patients with coronary atherosclerosis. J Electrocardiol. 2018;51:569-572. https://doi.org/10.1016/j.jelectrocard.2018.03.008

349

Pouliopoulos J, Chik WW, Kanthan A, Sivagangabalan G, Barry MA, Fahmy PN, Midekin C, Lu J, Kizana E, Thomas SP, et al. Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation. 2013; 128:229-2308. https://doi.org/10.1161/CIRCULATIONAHA.113.002238

350

Arslan E, Yiginer O, Yavasoglu I et al. Effect of uncomplicated obesity on QT interval in young men. Pol Arch Med Wewn 2010; 120: 209-213.

351

Li W, Bai Y, Sun K et al. Patients with metabolic syndrome have prolonged corrected QT interval (QTc). Clin Cardiol 2009;32: E93-E99.

352

Omran J, Firwana B, Bostick В et al. Obesity Reviews. 2016 Jun; 17(6):520-30. doi: 10.1111/obr.12390. Epub 2016 Mar 8.

353

Mukerji R, Petruc M, Fresen JL et al. Effect of weight loss after bariatric surgery on left ventricular mass and ventricular repolarization in normotensive morbidly obese patients. Am J Cardiol 2012; 110: 415-419.

354

Seyfeli E, Duru M, Kuvandik G et al. Effect of weight loss on QTc dispersion in obese subjects. Anadolu Kardiyol Derg 2006; 6: 126-129.

355

Isner JM, Sours HE, Paris AL, et al. Sudden,unexpected death in avid dieters using the liquid-protein-modified-fast diet. Observations in 17 patients and the role of the prolonged QT interval. Circulation. 1979;60(6):1401–1412.

356

Fisler JS. Cardiac effects of starvation and semistarvation diets: safety and mechanisms of action. Am J Clin Nutr. 1992;56(suppl 1):230S-234S.

357

Fumagalli S, Boni N, Padeletti M, Gori F, Boncinelli L, Valoti P, Baldasseroni S, Di Bari M, Masotti G, Padeletti L, et al. Determinants of thoracic electrical impedance in external electrical cardioversion of atrial fibrillation. Am J Cardiol. 2006;98:82-87. https://doi.org/10.1016/j.amjcard.2006.01.065

358

Jain R, Nallamothu BK, Chan PS; for the American Heart Association National Registry of Cardiopulmonary Resuscitation (NRCPR) Investigators. Body mass index and survival after in-hospital cardiac arrest. Circ Cardiovasc Qual Outcomes. 2010;3:490-497. https://doi.org/10.1161/CIRCOUTCOMES.109.912501

359

Ogunnaike B.O., Whitten C.W., Minhajuddin A. et al. Body mass index and outcomes of in-hospital ventricular tachycardia and ventricular fibrillation arrest. Resuscitation, 2016;105:156-160.

360

Lee J., Oh J., Lim T.H. et al. Comparison of optimal point on the sternum for chest compression between obese and normal weight individuals withrespect to body mass index, using computer tomography: A retrospective study. Resuscitation, 2015, 128:1-5.

361

Система непрямого массажа сердца LUCASTM2. Инструкция по применению. 2011:с33

362

Gupta T., Kolte D., Mohananey D. et al. Relation of obesity to survival after in-hospital cardiac arrest. Am. J. Cardiol. 2016;118(5):662-667.

363

Shahreyar M., Dang G., Waqas B.M. et al. Outcomes of in-hospital cardiopulmonary resuscitation in morbidly obese patients. JACC Clin.Electrophysiol. 2017;3(2):174-183.

364

Testori C., Sterz F., Losert H. et al. Cardiac arrest survivors with moderate elevated body mass index may have a better neurological outcome: a cohort study. Resuscitation. 2011;82(7):869-873.

365

Makoto A., Hagiwara S., Oshimaet K. al. Obesity was associated with worse neurological outcome among Japanese patients with out-of-hospital cardiac arrest // Intens. Care Med. 2018;44:665-666.

366

Shahreyar M, Dang G, Waqas Bashir M, Kumar G, Hussain J, Ahmad S, Pandey B, Thakur A, Bhandari S, Thandra K, et al. Outcomes of inhospital cardiopulmonary resuscitation in morbidly obese patients. JACC Clin Electrophysiol. 2017;3:174-183. https://doi.org/10.1016/j.jacep.2016.08.011

367

Choy В, Hansen E, Moss A et al. Relation of Body Mass Index to Sudden Cardiac Death and the Benefit of Implantable Cardioverter–Defibrillator in Patients With Left Ventricular Dysfunction After Healing of Myocardial Infarction. Am J Cardiol 2010 Mar 1;105(5):581-6.

368

Samanta R et al. Influence of BMI on inducible ventricular tachycardia and mortality in patients with myocardial infarction and left ventricular dysfunction: The obesity paradox. International Journal of Cardiology. 2018; 265:148-154.

369

Frankel DL, Burke MC, Callans DJ. Impact of Body Mass Index on Safety and Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator. J Am Coll Cardiol EP 2018 May 4(5):652-659.

370

Szepietowska et al. Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. Cardiovasc Diabetol (2016) 15:93 DOI 10.1186/s12933-016-0401-x.

371

Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал 2021; 26(7):4600, 128-189. https://doi.org/10.15829/1560-4071-2021-4600

372

Wong CX, Brooks AG, Lau DH, Leong DP, Sun MT, Sullivan T, Roberts-Thomson KC, Sanders P. Factors associated with the epidemic of hospitalizations due to atrial fibrillation. Am J Cardiol. 2012;110:1496-1499. https://doi.org/10.1016/j.amjcard.2012.07.011

373

Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123:1501-1508. https://doi.org/10.1161/CIRCULATIONAHA.110.009035

374

Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154-162. https://doi.org/10.1016/S0140-6736(14)61774-8 [PubMed: 25960110]

375

Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J. 2009;30:1113-1120. https://doi.org/10.1093/eurheartj/ehp076

376

Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE, Buring JE, Albert CM. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation: the WHS (Women’s Health Study). J Am Coll Cardiol. 2010;55:2319-2327. https://doi.org/10.1016/j.jacc.2010.02.029 [PubMed: 20488302]

377

Wong CX, Sullivan T, Sun MT, Mahajan R, Pathak RK, Middeldorp M, Twomey D, Ganesan AN, Rangnekar G, Roberts-Thomson KC, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1:139-152. https://doi.org/10.1016/j.jacep.2015.04.004

378

Tsang TS, Barnes ME, Miyasaka Y, Cha SS, Bailey KR, Verzosa GC, Seward JB, Gersh BJ. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J. 2008;29:2227-2233. https://doi.org/10.1093/eurheartj/ehn324

379

Habib RH, Zacharias A, Schwann TA, et al. Effects of obesity and small body size on operative and long-term outcomes of coronary artery bypass surgery: a propensity-matched analysis. Ann Thorac Surg. 2005;79(6):1976-1986.

380

Ector J, Dragusin O, Adriaenssens B et al. Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation. J Am Coll Cardiol 2007;50:234-242.

381

Shoemaker MB, Muhammad R, Farrell M et al. Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. Am J Cardiol 2013;111:368-373.

382

Sivasambu B et al. Increased Rates of Atrial Fibrillation Recurrence Following Pulmonary Vein Isolation in Overweight and Obese Patients. Cardiovasc Electrophysiol . 2018 Feb;29(2):239-245.

383

Glover BM et al. Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart 2018;0:1–7. https://doi.org/10.1136/heartjnl-2018-313490

384

Van Gelder IC, Crijns HJ, Van Glist W.H. et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991;68:41–46.

385

Rashba E., Bouhouch R., Koshy S. et al. A new algorithm for transthoracic cardioversion of atrial fibrillation based on body weight. Am J Cardiol 2001;88:1043-1045.

386

Vostrikov V.A. Cardioversion of atrial and ventricular tachyarrhythmias. p.245-272 in book “Guide to cardiac arrhythmias”, edited E.I. Chazov, S.P. Golitsyn, GEOTAR Media, Moscow 2008. Russian (Востриков В.А. Электроимпульсная терапия предсердных и желудочковых тахиаритмий. С. 245–272 в кн.: «Руководство по нарушениям ритма сердца». Под ред. Е.И. Чазова и С.П. Голицына. М: ГЭОТАР-Медиа 2008.)

387

P.M. Kistler, Sanders P, Morton J. Effect of Body Mass Index on Defibrillation Thresholds for Internal Cardioversion in Patients With Atrial Fibrillation Am J Cardiol 2004 Aug 1;94(3):370-2.

388

Blouin R.A., Kolpek J.H., Mann H.J. Influence of obesity on drug disposition. Clin. Pharm., 1987;6(9):706‒714.

389

Greenblatt H.K., Greenblatt D.J. Altered drug disposition following bariatric surgery: a research challenge. Clin. Pharmacokinet. 2015;54(6):573-579.

390

Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, et al. Longterm effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65:2159-2169. https://doi.org/10.1016/j.jacc.2015.03.002

391

Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060. https://doi.org/10.1001/jama.2013.280521

392

Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222-2231. https://doi.org/10.1016/j.jacc.2014.09.028

393

Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, Twomey D, Gallagher C, Hendriks JML, Linz D, et al. PREVEntion and regReSsive Effect of weight- loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study. Europace. 2018;20:1929-1935. https://doi.org/10.1093/europace/euy117

394

Gessler N et al. Supervised Obesity Reduction Trial for AF Ablation Patients: Results from the SORT-AF trial. Europace 2021 Oct 9;23(10):1548-1558.

395

Voskoboinik A et al. Cardioversion of Atrial Fibrillation in Obese Patients: Results from the Cardioversion-BMI Randomized Controlled Trial. J Cardiovasc Electrophysiol. 2019 Feb;30(2):155-161.

396

Российский кардиологический журнал 2021;26(7):4594. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. https://doi.org/10.15829/1560-4071-2021-4594

397

Влодзяновский В. В., Малкина Т. А., Соколов С. Ф. и соавт. Восстановление синусового ритма при персистирующей фибрилляции предсердий у больных с ожирением: новые возможности лекарственной кардиоверсии. Кардиология 2017;57(10):80–86.

398

Миронов Н.Ю., Влодзяновский В.В., Юричева Ю.А., и др. Проспективное рандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 1: методология исследования и оценка эффективности. Рациональная Фармакотерапия в Кардиологии. 2018;14(5):664-9. https://doi.org/10.20996/1819-6446-2018-14-5-664-669

399

Jastreboff AM, Kotz CM, Kahan S, Kelly AS, Heymsfield SB. Obesity as a disease: The Obesity Society 2018 position statement. Obesity (Silver Spring). 2019;27:7–9. https://doi.org/10.1002/oby.22378

400

Lavie CJ, Sharma A, Alpert MA, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis 2016; 58:393–400. https://doi.org/10.1016/j.pcad.2015.12.003

401

Agarwal M, et al. Relation Between Obesity and Survival in Patients Hospital-ized for Pulmonary Arterial Hypertension (from a Nationwide Inpatient Sample Database 2003 to 2011) Heart. Am J Cardiol. 2017; 120:489–493. https://doi.org/10.1016/j.amjcard.2017.04.051

402

Carbone S. Obesity paradox in cardiovascular disease: where do we stand?Vasc Health Risk Manag. 2019 May 1; 15:89-100. https://doi.org/10.2147/VHRM.S168946

403

Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations and man-agement. Transl Res 2014; 164:345–56. https://doi.org/10.1016/j.trsl.2014.04.010

404

Gruson D, Ahn SA, Rosseau MF: Biomarkers of inflammation and cardiac remodeling: the quest of relevant com-panions for the risk stratification of heart failure patients is still on going. Biochem Med (Zagreb) 2011; 21:254-263. https://doi.org/10.11613/BM.2011.035

405

Sung JK, Kim JY. Obesity and preclinical changes of cardiac geometry and function. Korean Circ J 2010; 40:5у223225–61. https://doi.org/10.4070/kcj.2010.40.2.55

406

Aurigemma GP, de Simone G, Fitzgibbons TP. Cardiac remodeling in obesi-ty. Circ Cardiovasc Imaging 2013; 6:142–52. https://doi.org/10.1161/CIRCIMAGING.111.964627

407

Peterson LR. Obesity and insulin resistance: effects on cardiac structure, function and substrate metabolism. Curr Hypertension Rep 2006; 8:451-6

408

Woodwiss AJ, Libhaber CD, Majane OH, et al. Obesity promotes left ven-tricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 2008; 21:1144–51. https://doi.org/10.1038/ajh.2008.252

409

Ren J, N Wu N, Wang S, R Sowers J, Zhang Y. Obesity cardiomyopathy: ev-idence, mechanisms, and therapeutic implications Physiol Rev. 2021 Oct 1;101(4):1745-1807. https://doi.org/10.1152/physrev.00030.2020

410

411

Carbone S, Billingsley HE, Rodriguez-Miguelez P, et al. Lean mass abnormal-ities in heart failure: the role of sar-copenia, sarcopenic obesity, and cachexia. Curr Probl Cardiol 2020; 45:100417. https://doi.org/10.1016/j.cpcardiol.2019.03.006

412

De Schutter A, Lavie CJ, Kachur S, et al. Body composition and mortality in a large cohort with preserved ejec-tion fraction: Untangling the obesity paradox. Mayo Clin Proc 2014;89:1072–9. https://doi.org/10.1016/j.mayocp.2014.04.025

413

Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart fail-ure with preserved ejection fraction: a randomized clinical trial. JAMA. (2016) 315:36–46. https://doi.org/10.1001/jama.2015.17346

414

Ross R., Blair S.N., Arena R., et al. Importance of Assessing Cardiorespirato-ry Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Sci-entific Statement from the American Heart Association. Circulation. 2016;134: e653–e699. https://doi.org/10.1161/CIR.0000000000000461

415

Kondamudi N., Haykowsky M., Forman D.E., et al. Exercise Training for Prevention and Treatment of Heart Failure. Prog. Cardiovasc. Dis. 2017; 60:115–120. https://doi.org/10.1016/j.pcad.2017.07.001

416

Pandey A, Garg S, Khunger M, et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation 2015; 132(19):1786–94. https://doi.org/10.1161/CIRCULATIONAHA.115.015853

417

Pandey A, Patel M, Gao A, et al. Changes in midlife fitness predicts heart fail-ure risk at a later age independent of interval development of cardiac and non-cardiac risk factors: the Cooper Center Longitudinal Study. Am Heart J 2015;169(2): 290–7 https://doi.org/10.1016/j.ahj.2014.10.017

418

Liu K, Daviglus ML, Loria CM, et al. Healthy lifestyle through young adult-hood and the presence of low cardiovascular disease risk profi le in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study. Circulation 2012; 125(8):996–1004. https://doi.org/10.1161/CIRCULATIONAHA.111.060681

419

Zadeh A, Dijk E, Prasad A, et al. Effect of aging and physical activity on left ventricular compliance. Circulation 2004;110(13):1799-1805. https://doi.org/10.1161/01.CIR.0000142863.71285.74

420

Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347 (5):305–13. https://doi.org/10.1056/NEJMoa020245

421

Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. (2008) Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 156(1):13–22. https://doi.org/10.1016/j.ahj.2008.02.014

422

Padwal R, McAlister F, McMurray J, et al. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of indi-vidual patient data. Int J Obes (Lond) 2014; 38 (8): 1110-4. https://doi.org/10.1038/ijo.2013.203

423

Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity par-adox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1(2):98. https://doi.org/10.1016/j.jchf.2013.01.006

424

Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M., Sohanpal S., Sanders S., Hobbs FDR. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009; 13:1–207

425

Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., Van Velzen E., Wielders J.P., Zuithoff N.P., Rutten F.H., Hoes A.W. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011; 13:518–527

426

Weingärtner O, Hasan T, Böhm M.Pathophysiology and differential diagnosis of dyspnea Herz. 2004 Sep; 29(6):595-601. https://doi.org/10.1007/s00059-004-2594-0

427

Fries R.Differential diagnosis of leg edema. MMW Fortschr Med. 2004 Apr 15; 146(16):39-4

428

Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr, Heart Failure Association of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715731

429

Wang T, Larson M, Levy D, Benjamin E, Leip E, Wilson P, Ramachandran S. Impact of Obesity on Plasma Natriuretic Peptide Levels. Circulation. 2004;109:594–600.

430

Bayés-Genis A, Lloyd-Jones DM, Van Kimmenade RRJ, Lainchbury JG, Richards AM, Ordoñez-Llanos J, Santaló M, Pinto YM, Januzzi JL. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007; 167: 400–407

431

Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003 Jun 4;41(11):2010-7. https://doi.org/10.1016/s0735-1097(03)00405-4

432

Daniels LB, Clopton P, Bhalla V. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151:999–1005

433

Jankowska EA , von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34:816–826.

434

Filippatos G, Farmakis D, Parissis J. Renal dysfunction and heart failure: things are seldom what they seem. Eur Heart J 2014; 35:416–418

435

Ewid M., Sherif H., Allihimy A.S. et al. AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction. BMC Res Notes. 2020; 13: 178. https://doi.org/10.1186/s13104-020-05031-3

436

Felipe Martinez. Thyroid hormones and heart failure. Heart Failure Reviews volume 21, pages361–364(2016).

437

Tribouilloy C, Rusinaru D, Mahjoub H, et al. Impact of echocardiography in patients hospitalized for heart failure: a prospective observational study. Arch Cardiovasc Dis. 2008;101:465–473.

438

Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in heart failure: applications, utility, and new horizons. JAm Coll Cardiol. 2007; 50:381–396.

439

Senni M, Rodeheffer RJ, Tribouilloy CM, et al. Use of echocardiography in the management of congestive heart failure in the community. J Am Coll Cardiol. 1999; 33:164–170.

440

Agha SA, Kalogeropoulos AP, Shih J, et al. Echocardiography and risk prediction in advanced heart failure: incremental value over clinical markers. J Card Fail. 2009; 15: 586–592.

441

Hoffmann R, von Bardeleben S, ten Cate F, et al. Assessment of systolic left ventricular function: a multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast-enhanced echocardiography. Eur Heart J 2005 Mar; 26(6):607-16.

442

Hoffmann R, Barletta G, von Bardeleben S, Vanoverschelde JL, Kasprzak J, Greis C, et al. Analysis of left ventricular volumes and function—a multicenter comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrast enhanced 2D and 3D echocardiography. J Am Soc Echocardiogr 2014; 27:292-301

443

Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K., Parrillo J.E., Calvin J.E. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure.Am J Med 2002;112:437–445.

444

Hawkins N.M., Petrie M.C., Jhund P.S., ChalmersG.W., Dunn F.G., McMurray J.J.V. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–139.

445

Bozkurt B, Aguilar D, Deswal A, et al; Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134: e535–e578. https://doi.org/10.1161/CIR.0000000000000450

446

Sundstrom J, Bruze G, Ottosson J, et al. Weight loss and heart failure: a na-tionwide study of gastric bypass surgery versus intensive lifestyle treatment. Cir-culation 2017; 135(17):1577–1585. https://doi.org/10.1161/CIRCULATIONAHA.116.025629

447

Lavie CJ, Laddu D, Arena R, et al. Reprint of: healthy weight and obesity prevention: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(Pt B):3027–3052. https://doi.org/10.1016/j.jacc.2018.10.024

448

Maggioni A.Р., Anand I., Gottlieb S.O. et al. Effects of Valsartan on Morbidi-ty and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme inhibitors J Am Coll Cardiol. 2002;40 (8):1414–1421

449

Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316 (23):1429–1435.

450

Effect of ramipril on mortality and morbidity of survivors of acute myocardi-al infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342 (8875):821–828.

451

Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27:2338–2345.

452

Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril at-tenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995 Dec;16(12):1892-9. https://doi.org/10.1093/oxfordjournals.eurheartj.a060844

453

McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L.,Shi V.C., Solomon S.D., Swedberg K., Zile M.R., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371: 993–1004.

454

Packer M., Bristow M.R., Cohn J.N. et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in pa-tients with chronic heart failure. N Engl J Med 1996; 334 (21):1349–1355.

455

Gattis W.A., O’Connor C.M., Leimberger J.D. et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91 (2):169–174.

456

Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbid-ity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717.

457

Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with systol-ic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11–21.

458

Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351 (6):543–551

459

McMurray J.J.V., Solomon S.D., Inzucchi S.E., et all. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. September 19, 2019. https://doi.org/10.1056/NEJMoa1911303

460

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New Engl Journal Med. 2020;383:1413-24. https://doi.org/10.1056/NEJMoa2022190

461

Cleland JGF, Bunting KV, Flather MD, et all. Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range,and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35.

462

Solomon SD, McMurray JJV, Anand IS, et all. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-1620

463

Yusuf S, Pfeffer MA, Swedberg K, et all. CHARM Investigators and Com-mittees. Effects of candesartan in patients with chronic heart failure and pre-served left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-781.

464

Pitt B, Pfeffer MA, Assmann SF, et all. TOPCAT Investigators. Spironolac-tone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-1392.

465

Solomon SD, Vaduganathan M, Claggett BL, et all. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020;141:352-361.

466

Flather MD, Shibata MC, Coats AJ, et all. SENIORS Investigators. Ran-domized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-225.

467

Cleland JGF, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization — Heart Failure (CARE-HF) trial. Eur J Heart Fail. 2012;14:628-34. Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013;34:2592-9

468

Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547-56.

469

Wyse D, Friedman PL, Epstein AE. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-83

470

Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J. 2000;21:2071-8.

471

Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-302.

472

Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-5

473

Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-83.

474

Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874-9.

475

Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverterdefibrillators. N Engl J Med. 2005;353:1471-80.

476

Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE): a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017; 19:69–77. https://doi.org/10.1002/ejhf.

The authors declare that there are no conflicts of interest present.